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1. SUMMARY 
 
It was the introduction of the soft ionization techniques electrospray ionization (ESI) 
and matrix-assisted laser desorption/ionization (MALDI), and the improvement of the 
ion analysis techniques, e.g. tandem mass spectrometry (MS/MS), which made MS one 
of the key technologies in the clinical laboratory. Today, MS is used in a wide range of 
fields, such as multiple analyte screening for inborn errors of metabolism, therapeutic 
drug monitoring, drug doping analysis, toxicology, pharmacology, peptide and protein 
chemistry, or steroid hormone profiling. 
I focus in this "Habilitationsschrift" on the development of soft ionization mass 
spectrometry techniques and their application in pediatric laboratory medicine for the 
detection of biomarkers in body fluids of children with genetic disorders. I exemplify 
the use of these techniques for the detection of variant human proteins (hemoglobin 
variants and minor hemoglobins), the detection of changes in posttranslational 
modification of human proteins (glycosylation), and for the quantification of metabolic 
compounds (acylcarnitines and acylglycines).  
The studies presented here have contributed 1) to improved detection of 
hemoglobinopathies and to the discovery of the reason for the elevated HbA2 in patients 
with sickle cell anemia, 2) to the improved diagnosis of patients with congenital 
disorders of glycosylation by a specific and sensitive method for the analysis of 
transferrin, its different glycosylated isoforms, and 1-acid glycoprotein, and 3) to the 
diagnosis of the rare palmitoyltransferase type I deficiency by acylcarnitine analysis and 
the diagnosis of organic aciduria or fatty acid oxidation disorders by determination of 
urinary acylglycines. 
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2. LIST OF ABBREVIATIOS 
 
CDG  Congenital Disorders of Glycosylation 
CPT-I  Carnitine Palmitoyltransferase Type I 
Da  Dalton (mass units used in mass spectrometry) 
ESI  Electrospray Ionization 
Hb   Hemoglobin 
Hb S  Sickle Cell Anemia 
MALDI-TOF Matrix-assisted Laser Desorption/Ionization Time-of-Flight 
MS  Mass Spectrometry 
MS/MS  Tandem Mass Spectrometry 
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3. BACKGROUND 
 
Mass spectrometry (MS) is one of the most powerful and versatile technique, whose 
basic principles were developed in the early 20th century and that has contributed 
substantially to progress in medicine, biochemistry, and molecular biology. In medicine, 
the use of MS has expanded from research to clinical routine application. The first 
medically relevant applications of this technique were the analyses of thermally highly 
stable and vaporizable substances such as steroids or fatty acids that were analyzed by 
gas chromatography coupled to mass spectrometry. In pediatric laboratory medicine the 
analysis of urinary organic acids by MS turned out to be a powerful clinical tool for 
detection and identification of inborn errors of metabolism and for therapy monitoring. 
However, substances with a molecular weight of more than 1000 Da cannot be analyzed 
by gas chromatography-mass spectrometry. The development of the innovative new 
ionization techniques, electrospray ionization (ESI) and matrix-assisted laser 
desorption/ionization (MALDI) by J. B. Fenn and K. Tanaka, respectively, led to a 
breakthrough for mass spectrometry methods in biomedical sciences in the 1990s. 
These techniques allow polar or thermally unstable compounds of high molecular 
weight to be ionized and to transfer these ions into the gas phase. These techniques are 
"soft", meaning that the analyte ions are not thermally activated and they do not decay 
into fragment ions during ionization. MS has thus become applicable to almost all 
biological compounds, even to macromolecular biopolymers, such as peptides, proteins, 
oligosaccharides, or oligonucleotides. Emphasizing the outstanding importance of these 
ionization methods, in 2002 the Nobel Prize in Chemistry was awarded to John B. Fenn 
and Koichi Tanaka for their fundamental developments of soft ionization techniques. 
The second breakthrough, which led the widespread use of mass spectrometry in the 
clinical laboratory, was the improvement of the ion analysis technique. In this context, 
tandem mass spectrometry (MS/MS) is the state of the art analytical technique that 
enables highly specific detection and/or identification of known and unknown chemical 
compounds. With MS/MS, it is now possible to analyze more than 200 substances in a 
single analytical process. This capability of MS is now widely used for the detection, in 
children, of inborn errors of metabolism (for example in national newborn screening 
programs) or in many hospitals for drug monitoring.  
I will focus in this summary on the development of soft ionization mass spectrometry 
techniques and their application in the clinical laboratory for the detection of 
biomarkers in human body fluids of children with genetic disorders. I will exemplify the 
use of these techniques for the detection of variant human proteins (hemoglobin variants 
and minor hemoglobins), the detection of changes in posttranslational modification of 
human proteins (glycosylation), and for the quantification of metabolic compounds 
(acylcarnitines and acylglycines).  
Hemoglobinopathies are a group of genetic disorders affecting red blood cells with 
abnormal hemoglobin (Hb). Structural Hb variants are typically due to a point mutation 
in a globin gene that produces a single amino acid substitution in a globin chain. 
Although most of these variants are of limited clinical significance, many of them, such 
as homozygous sickle cell anemia (Hb S) and Hb C, produce severe clinical 
manifestations. Worldwide, an estimated 150 million people carry Hb variants, and 
hemoglobinopathies are the most common inherited disorders, constituting a significant 
healthcare problem. Until now, more than 900 Hb variants have been identified and 
listed in the globin gene server database. The predominant Hb variants listed in this 
database are charge-difference variants, a feature attributable to historical and 
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methodological reasons. In contrast, MS allows the detection of electrophoretically and 
chromatographically silent variants not detected by the electrophoretic and 
chromatographic methods previously used to diagnose hemoglobin variants. Some of 
these variants have no clinical manifestations but could cause substantial overestimation 
of HbA1c, the important marker for diabetes mellitus. 
Furthermore, major and minor Hb components occur in erythrocytes. Examples of 
major Hb components are HbA, a tetramer consisting of 2 - and 2 -globin chains 
( 2 2) that is predominant after childhood and during adult life, or HbF ( 2 2), which is 
the main Hb during fetal development. The minor species are labeled as HbA1a through 
HbA1e according to their elution order in cation-exchange high performance liquid 
chromatography. The heterogeneity of human Hb arises mainly from posttranslational 
glycation. The exact quantification of minor Hbs has crucial diagnostic implications. 
For example, HbA1c is a marker for diabetes mellitus, or HbA2 ( 2 2) is increased in -
thalassemias. Cation-exchange chromatography is commonly used for the separation of 
Hb fractions and quantification of the minor Hbs. However, this method can reveal 
falsely elevated concentrations of some minor Hbs in the presence of abnormal Hbs, 
thus leading to an incorrect diagnosis. With MS techniques, it is possible to investigate 
the globin chains constituting the different major and minor Hbs in detail, 
circumventing such false interpretation. 
MS is the method of choice for the analysis of posttranslational modifications of 
proteins. Posttranslational modifications are critical for the proper function of proteins 
in cells, and the most abundant posttranslational modifications in humans are 
glycosylation and phosphorylation of proteins. In several human diseases, such as 
congenital disorders of glycosylation or glycoproteinoses, glycosylation is disturbed. 
The diagnosis of congenital disorders of glycosylation is based on the detection of 
alterations in the oligosaccharide structure of the glycoproteins, such as transferrin or 
1-acid glycoprotein. Most currently used methods are charge-based separation 
procedures using anion-exchange chromatography or isoelectric focusing. MS is an 
alternative and specific method for the analysis of transferrin isoforms (ESI-MS) and 
for the determination of glycans (MALDI-TOF-MS) that were enzymatically cleaved 
from 1-acid glycoprotein or transferrin.  
The use of ESI-MS/MS has revolutionized the newborn screening programs around the 
world and led to an exemplary change. Before ESI-MS/MS, a single analytical method 
was needed for each single disorder. Applying ESI-MS/MS, more than 30 disorders can 
now be analyzed within a single measurement. Several amino acidemias, fatty acid 
oxidation disorders, and organic acidemias are now detectable in the newborn screening 
programs through the analysis of amino acids and acylcarnitines isolated from dried 
blood spots on filter paper cards (Guthrie cards). The most frequent disorders are 
phenylketonuria and medium-chain acyl-CoA-dehydrogenase deficiency, but also rare 
disorders such as carnitine palmitoyltransferase type I (CPT-I) deficiency are detectable 
with this technique. In CPT-I deficiency, long-chain fatty acids are not transferred from 
CoA to carnitine to form acylcarnitines by palmitoyl-CoA:L-carnitine O-
palmitoyltransferase. Thus, they cannot enter the mitochondria for subsequent -
oxidation. Children with CPT-I deficiency show decreased long-chain acylcarnitines, 
such as palmitoylcarnitine and stearoylcarnitine, and usually endure with life-
threatening attacks of fasting hypoketotic hypoglycemia and coma during the first 2 
years of life. Persistent neurological deficits are common. Early detection of CPT-I 
deficiency by newborn screening might prevent both a neonatal life-threatening 
metabolic decompensation and commonly observed neurological deficits.  
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Another group of important metabolites that can be analyzed by ESI-MS/MS are 
acylglycines. Glycine conjugation serves as a valuable detoxification system of the 
human body. The mitochondrial enzyme glycine-N-acylase is responsible for 
conjugation of glycine with exogenous compounds to enhance their excretion in urine. 
Furthermore, glycine conjugation is also an effective detoxification system for 
endogenous acyl-CoA esters, preventing accumulation of acyl-CoA esters causing 
several inherited metabolic diseases. Elevated levels of acylglycines in urine, e.g. 
isovaleroylglycine or propionylglycine in isovaleric or propionic aciduria, are the result 
of accumulation of the corresponding acyl-CoA esters in the mitochondrion. Therefore, 
the study of acylglycines in urine with MS is a significant diagnostic strategy for fatty 
acid oxidation defects and amino and organic acidurias.  
 
 
 
4.  MASS SPECTROMETRY IN HEMOGLOBIN ANALYSIS 
  (APPENDIX 1 & 2)  
 
4.1 Enhanced Detection of Hemoglobin Variants by MS 
In this study, we investigated whether Hb variants are possibly missed when only 
conventional techniques, such as electrophoretic or chromatographic methods, are 
applied for Hb analysis. Firstly, we calculated, on the basis of the DNA variants, every 
possible protein variant (only single-point mutations) of the - and -globin chains to 
obtain the proportion of detected vs. not yet detected Hb variants. To assess whether an 
Hb variant should be detectable with electrophoretic or chromatographic methods (the 
classical methods), the pI and the hydrophobicity indices of all Hb - and -variants 
were calculated. During a 5-year period, the globin chains of 2105 patients were 
analyzed with cation-exchange and reversed-phase high performance liquid 
chromatography, and additionally with electrospray ionization or MALDI-TOF MS.  
Database evaluation revealed that 43.2% of all possible Hb - and -chain variants have 
been detected to date. Currently, 68.2% of the possible charge difference variants and 
only 28.7% of the neutral variants have been found, confirming the strong 
predomination of charge-difference variants compared to neutral (noncharge difference) 
variants. Experimentally, among the 2105 Hb samples, we identified 4 samples with Hb 
variants that were exclusively found by MS and are chromatographically silent (neutral 
variants). Two of these were new Hb variants, Hb Zurich-Hottingen and Hb Zurich-
Langstrasse.  
This study shows that we would have missed 4 out of 2105 samples (0.2%) or 1% of the 
abnormal samples without the use of MS analysis. MS allows the detection of 
electrophoretically and chromatographically silent Hb variants and complements 
traditional techniques, such as electrophoresis at alkaline or acidic pH or 
chromatographic assays. Application of MS improves the sensitivity of Hb analysis. We 
concluded that the combination of MS with traditional methods is optimal for the 
detection of Hb variants.  
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4.2 Minor Hemoglobins Analyzed by MALDI-TOF-MS 
In this study, minor Hb fractions in lysate samples were separated using cation-
exchange high performance liquid chromatography. The different globin chains 
contained in the minor Hb fractions were further analyzed by MALDI-TOF MS and 
identified by their molecular masses. Posttranslational modifications of proteins were 
identified by digestion of the proteins with endoproteinases before MALDI-TOF MS 
analysis of the resulting peptides.  
We analyzed the HbH, Hb Barts, HbA1b, pre-HbA1c, HbA1c, HbF1, HbF, HbA1d3a, 
HbA2, and HbC1 fractions from control and pathological blood samples. We identified 
several posttranslational modifications of the globin chains, such as pyruvatization, 
glycation, acetylation, carbamylation, and acetaldehyde adduct formation. Analysis of 
the HbA2 fractions of patients with Hb S revealed 4 different globin chains. We found, 
in addition to the expected - and -chains, the carbamylated - and the 
S
-chains, 
suggesting that this fraction contains at least 2 different minor hemoglobins. 
The native and posttranslationally modified globin chains in minor and major Hbs are 
unambiguously identified by MALDI-TOF-MS in control and pathological blood 
samples. A minor Hb containing the carbamylated - and the 
S
-chain elutes at the 
same time as normal HbA2 ( 2 2) and thus leads to falsely increased HbA2 values in 
patients with Hb S when blood is analyzed with cation-exchange high performance 
liquid chromatography. 
 
 
 
 
5 . GLYCOSYLATION OF PROTEINS: MASS    
  SPECTROMETRIC ANALYSIS (APPENDIX 3 & 4) 
 
5.1 MS Analysis of Transferrin 
In this study, a versatile new procedure for the analysis of transferrin and its glycated 
isoforms isolated from human body fluids, such as serum, plasma, and cerebrospinal 
fluid, is presented. The method is based on a three-step procedure: (i) isolation of 
transferrin using anion-exchange chromatography; (ii) concentration of the transferrin 
fraction; (iii) detection of the isoforms with liquid chromatography-electrospray 
ionization mass spectrometry. 
According to their respective molecular masses, up to ten differently glycosylated 
isoforms of transferrin were identified in a serum sample from a patient with a 
congenital disorder of glycosylation type Ia (CDG-Ia). The method was further applied 
to different pathological samples from patients with CDG-Ib, CDG-Ic, CDG-Ie, CDG-
If, CDG-IIa, as well as samples from alcohol abusers. 
In contrast to most common procedures that are based on electrophoretic or 
chromatographic methods, we identified the transferrin isoforms according to their 
molecular masses. Our method enables an unambiguous and more specific 
determination of the different isoforms. It is applicable for the diagnosis of congenital 
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disorders of glycosylation and can be used with several types of samples (serum, 
plasma, CSF) and may also be applied to plasma samples spotted on Guthrie cards.  
 
5.2 Effect of Glycosylation on the Protein Spot Pattern 
Single proteins, when analyzed with 2-D-PAGE, often show multiple spots due to 
posttranslational modifications. In gels of human body fluids, the spot patterns facilitate 
the assignment and identification of the proteins. We used two-dimensional gel 
electrophoresis, MALDI-TOF MS, and ESI-MS for the analysis, identification and 
characterization of the human glycoproteins 1-acid glycoprotein and transferrin and 
their corresponding glycans. 
We analyzed serum from patients suffering from congenital disorders of glycosylation 
in which glycoproteins are strongly impacted and exhibit highly distinguishable spot 
patterns compared to healthy controls. We found a complex protein spot pattern for the 
proteins 1-acid glycoprotein and transferrin that are both used as protein markers for 
congenital disorders of glycosylation. 1-acid glycoprotein contains 5 glycosylation 
sites, which results in a complex microheterogeneity of the glycoprotein spot pattern. 
On the other hand, transferrin is a glycoprotein with only 2 glycosylation sites, and 
therefore, we expected a very simple spot pattern for transferrin. However, transferrin 
also exhibited a complex spot pattern in two-dimensional gel electrophoresis. As with 
1-acid glycoprotein, we excised the different spots from the gel, cleaved off the 
glycans from the protein backbone and analyzed the resulting glycans with MALDI-
TOF-MS. For transferrin, we found only the expected biantennary N-linked glycans, 
therefore, we concluded that glycosylation is not responsible for the complex spot 
pattern found in two-dimensional gel electrophoresis. We then digested human 
transferrin with endoproteinases and analyzed the resulting peptides with MALDI-TOF-
MS. A peptide was detected containing a cysteine residue that was oxidized to its 
corresponding sulfinic acid. 
In contrast to 1-acid glycoprotein, the protein spots of transferrin cannot be explained 
by glycosylation. We found strong evidence that oxidation of cysteine is responsible for 
the spot pattern. This study contradicts the commonly accepted assumption that the 
multiple protein spots of transferrin observed in two-dimensional gel electrophoresis are 
due, as in 1-acid glycoprotein, to the glycosylation of the protein. 
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6. APPLICATION OF TANDEM MASS SPECTROMETRY 
  (APPENDIX 5 & 6) 
 
6.1 Aclycarnitine Profile in CPT-I 
Carnitine palmitoyltransferase type I (CPT-I) is a rare disorder of hepatic mitochondrial 
long-chain fatty acid oxidation. As CPT-I deficiency may be amenable to treatment, its 
inclusion into the electrospray ionization-tandem mass spectrometry based newborn 
screening is desirable, both to estimate its incidence and to allow for early diagnosis. As 
early detection of CPT-I deficiency in newborns could prevent potentially life-
threatening complications, we tested whether CPT-I deficiency might be diagnosed by 
ESI-MS/MS. 
A blood spot dried on filter paper was extracted with methanol and acylcarnitines were 
derivatized to their corresponding butylesters. The samples were analyzed by ESI-
MS/MS and in the three patients with CPT-I deficiency, we found an invariably 
increased ratio of free carnitine to the sum of palmitoylcarnitine and stearoylcarnitine. 
The ratio in patients was 5- to 60-fold higher than the ratio for the 99.9th centile of the 
normal newborn population. No overlap with the values of children that were known to 
be supplemented with carnitine was detected. 
ESI-MS/MS provides a highly specific acylcarnitine profile from dried-blood samples. 
The ratio of free carnitine to the sum of palmitoylcarnitine and stearoylcarnitine is 
highly specific for CPT-I deficiency and may allow presymptomatic diagnosis in 
newborn screening programs. Early detection of CPT-I deficiency by newborn 
screening might prevent both a neonatal life-threatening metabolic decompensation and 
commonly observed neurological deficits. 
 
6.2 Urinary Acylglycines Analyzed by ESI-MS/MS 
We analyzed the urinary acylglycine excretion in 26 patients with mitochondrial energy 
metabolism disorders and in 55 patients with organic acidurias by electrospray 
ionization tandem mass spectrometry. Urinary concentrations of the different 
acylglycines were quantified using deuterated internal standards, and normal values for 
most of the important acylglycines were established.  
In medium-chain acyl-CoA dehydrogenase deficiency, multiple acyl-CoA 
dehydrogenase deficiency, isovaleric aciduria, propionic aciduria, and 3-
methylcrotonylglycinuria, the typical glycine conjugates were always detected. 
Pathological acylglycine profiles, even if not specific for the disease, were detected in 
methylmalonic aciduria, multiple carboxylase deficiency, and 3-hydroxy-3-
methylglutaric aciduria. In all these diseases acylglycine excretion seems to be less 
influenced by the clinical status than organic acid excretion. 
All of the studies on acylcarnitines so far have focused mainly on medium-chain acyl-
CoA dehydrogenase deficiency or organic acidurias. We presented the analysis of 
urinary acylglycine profiles in a wide spectrum of disorders. From our results, we 
concluded that urinary acylglycine analysis by ESI-MS/MS is a powerful diagnostic 
tool for some mitochondrial energy metabolism defects and organic aciduria. The 
method is complementary to organic acids and acylcarnitine profiles. 
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7. CONCLUSIONS 
 
In conclusion, our studies presented here have contributed 1) to improved detection of 
hemoglobinopathies and to the discovery of the reason for the elevated HbA2 in patients 
with sickle cell anemia, 2) to the improved diagnosis of patients with congenital 
disorders of glycosylation by a specific and sensitive method for the analysis of 
transferrin, its different glycosylated isoforms, and 1-acid glycoprotein, and 3) to the 
diagnosis of the rare palmitoyltransferase type I deficiency by acylcarnitine analysis and 
the diagnosis of organic aciduria or fatty acid oxidation disorders by determination of 
urinary acylglycines. 
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Mass Spectrometry: A Tool for Enhanced
Detection of Hemoglobin Variants
Peter Kleinert,1 Marlis Schmid,2 Karin Zurbriggen,2 Oliver Speer,2 Markus Schmugge,2 Bernd Roschitzki,3
Silke S. Durka,1 Urs Leopold,1 Thomas Kuster,1 Claus W. Heizmann,1 Hannes Frischknecht,4
and Heinz Troxler1*
BACKGROUND: More than 900 hemoglobin (Hb) vari-
ants are currently known. Common techniques used in
Hb analysis are electrophoretic and chromatographic
assays. In our laboratory, we routinely apply chro-
matographic methods. To ascertain whether Hb vari-
ants are missed with our procedures, we additionally
analyzed all samples with mass spectrometry (MS).
METHODS: Database evaluation was performed using all
entries made in the Hb variant database HbVar, and
possible Hb variants were calculated based on DNA
variations. During a 5-year period, we analyzed 2105
lysates with cation-exchange HPLC (PolyCAT A col-
umn) and reversed-phase HPLC and additionally with
electrospray ionization or MALDI-TOF MS. Globin
chains were identified by their molecular masses.
RESULTS: Database evaluation revealed that 43.2% of all
possible Hb- and -chain variants were found to date
(considering only single-point mutations). Currently,
68.2% of the possible charge difference variants and
only 28.7% of the neutral variants are found. Among
2105 Hb samples we identified 4 samples with Hb vari-
ants that were detected only with the MS method; 2
were new Hb variants (Hb Zurich-Hottingen and Hb
Zurich-Langstrasse). With cation-exchange HPLC, 1
sample was found to be a -thalassemia and was iden-
tified by MS to be a -variant (Hb Malay). More com-
mon variants, such as Hb C, Hb D, and Hb E, and
thalassemias could not be detected with the MS
method.
CONCLUSIONS: Application of MS improves the sensitiv-
ity of Hb analysis. The combination of MS with elec-
trophoretic and chromatographic methods is optimal
for the detection of Hb variants.
© 2007 American Association for Clinical Chemistry
Hemoglobinopathies are a group of disorders affecting
red blood cells with abnormal hemoglobin (Hb).5
Thalassemias, in contrast, are characterized by im-
paired synthesis of normal globins (1, 2 ). Structural
Hb variants are typically due to a point mutation in a
globin gene that produces a single amino acid substitu-
tion in a globin chain. Although most of these variants
are of limited clinical significance, many of them, such
as homozygous Hb S and Hb C, produce severe clinical
manifestations. Furthermore, variants with no clinical
manifestations could cause substantial overestimation
of HbA1c, the important marker for diabetes mellitus.
Worldwide, an estimated 150 million people carry Hb
variants (3 ), and hemoglobinopathies are the com-
monest inherited disorders, constituting a significant
healthcare problem (4 ). Therefore, reliable detection
and identification methods are essential.
Since the pioneering study of Linus Pauling in
1949 (5 ), in which the different electrophoretic mobil-
ities of sickle cell anemia Hb and normal Hb were de-
scribed, more than 900 Hb variants have been identi-
fied and listed in the globin gene server (HbVar)
database (6, 7 ). In this database, Hb variants leading to
a charge difference are significantly overrepresented
compared with neutral Hb variants. This result is sur-
prising, because only 5 of the 20 amino acids contain
either a basic (Lys, Arg, His) or an acidic (Asp, Glu) side
chain, whereas the other 15 amino acid side chains are
uncharged. Thirty-six of 141 amino acids in the
-chain and 38 of 146 residues in the -chain are
charged residues. This disproportion is explained by
the characteristics of the analysis technique used; elec-
trophoresis at alkaline or acidic pH has been the meth-
ods of choice for Hb analysis, although chromato-
graphic assays were also widely used (8 –11 ).
Reversed-phase (RP) and cation-exchange HPLC
are often applied, and the latter enables the quantifica-
Divisions of 1 Clinical Chemistry and Biochemistry and 2 Hematology, Department
of Pediatrics, University of Zurich, Zurich, Switzerland; 3 Functional Genomics
Center Zurich, Zurich, Switzerland; and 4 IMD Institute for Medical and Molecular
Diagnostics Ltd., Zurich, Switzerland.
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tion of various Hb fractions, including HbF and HbA2,
along with Hb variants (2, 10 ). Therefore, this method
is well suited for the detection of hemoglobinopathies
and some thalassemias. The separation power of the
electrophoretic methods is mainly dependent on the
charge state of the Hb variant, and in cation-exchange
HPLC, separation is due to the affinity of the Hb cat-
ions to the polyaspartic acid-coated stationary phase.
In contrast, in RP HPLC, the separation is based on the
hydrophobicity of the Hb chains.
During the last 3 decades, mass spectrometry
(MS), a technique that is widely used in clinical chem-
istry, laboratory medicine, and research, found its way
into the field of Hb analysis. In 1981, Wada et al. (12 )
pioneered the analysis of tryptic peptides of Hb by MS.
The development of the soft ionization techniques
electrospray ionization (ESI) and MALDI made it pos-
sible to use MS to study intact globin chains. In 1990,
the 1st application of ESI MS involving intact Hb
chains was reported by Falick et al. (13 ). ESI or
MALDI-TOF MS is now becoming a common auxil-
iary method applied in routine Hb analysis. The use of
MS techniques has led to the discovery of more than 60
new mutations (14 ), and even the intact Hb tetramer
can be analyzed using a nanoESI MS technique (15 ).
Furthermore, MALDI-TOF MS is a highly sensitive
method that enables the analysis of Hb chains from a
single red blood cell (16 ). Final identification of a vari-
ant is achieved either by molecular biology techniques
or by protein sequence analysis, in which MS now also
occupies a key position (17 ). In (18 ), variants with mu-
tation sites close to the termini of the -chain were
identified by ESI MS/MS of the intact Hb chain.
In this study, we calculated the pI, the hydropho-
bicity index, and the mass difference of detected
(entries in the HbVar database) and undiscovered
(theoretically possible) Hb - and -variants. We sta-
tistically assessed the incidence of charge-, hydropho-
bicity-, and mass-difference variants. Experimentally,
we used MS to investigate whether Hb variants are
missed when 2 chromatographic techniques (cation-
exchange and RP HPLC) are applied for Hb analysis.
Materials and Methods
DATABASE ANALYSIS AND CALCULATIONS
All entries made in the globin gene server (HbVar) da-
tabase (7 ) until July 19, 2007, were included in this
study, but only exonic single-point mutations leading
to a single amino acid change are considered. Also,
effects of protein processing aberrations in Hb vari-
ants, e.g., in Hb Marseille or Hb Raleigh, were disre-
garded. The pIs of the protein variants were calculated
using the method of Bjellqvist et al. (19 ) with the soft-
ware accessible on the ExPASy homepage (http://www.
expasy.ch). Variants with a pI difference 0.050 units
compared with the pI of the normal chains were con-
sidered as charge difference variants. Hydrophobicity
values were calculated using the method described by
Kyte and Doolittle (20 ). Variants with hydrophobicity
values that differ more than 0.010 units from the nor-
mal chains were considered as hydrophobicity change
variants.
BLOOD SAMPLES
During a 5-year period, 2105 blood samples from dif-
ferent patients were collected with EDTA or heparin as
anticoagulant, stored at 4 °C, and analyzed within 4 h.
Hemolysates were prepared for chromatographic anal-
ysis by lysing washed erythrocytes in 1 mmol/L KCN.
Hb ANALYSIS WITH HPLC AND IEF
We performed cation-exchange HPLC (PolyCAT A
column) according to (21 ) and RP HPLC as described
in (22 ). Samples that were found with chromato-
graphical methods to be abnormal were confirmed by
IEF according to (23 ).
ESI AND MALDI-TOF MS
A PerkinElmer SCIEX API 365 LC/MS/MS system
equipped with a PerkinElmer Series 200 autosampler
was used for ESI MS analysis. Mass spectra were ac-
quired in the range of m/z 700 to 1800, with step size
0.1. Samples were diluted 1:150 in acetonitrile-water
(50:50 by volume) containing 1 mL CH3COOH/L; 10
L of the diluted lysate samples was injected. An
autoflex® system (Bruker Daltonics®) was used for
MALDI-TOF MS of the lysate samples. The mass reso-
lution at 15 kDa was approximately 750 (m/m,
FWHM). Samples were diluted 1:150 in acetonitrile-
water (50:50 by volume) containing 1 mL CH3COOH/L.
The samples were analyzed by the overlayer method. A
thin layer of sinapinic acid solution (saturated solution in
ethanol) was applied to a ground-steel MALDI target.
Equal volumes of protein sample and a saturated sinap-
inic acid solution (containing, per liter, 330 mL CH3CN
and 1 mL trifluoroacetic acid) were mixed, and 0.5 L of
the mixture was applied to the thin layer and dried at
room temperature.
We analyzed 57% of the samples with ESI MS and
43% of the samples with MALDI-TOF MS.
DNA ANALYSIS
DNA was prepared from peripheral blood using
the QIAamp DNA Blood Mini Kit (Qiagen) and am-
plified using 2 specific primer sets for the -globin
gene (sense primer, 5-GCAATTTGTACTGATGG-
TATGG-3, and antisense primer, 5-CCACACTGAT-
GCAATCATTCG-3). PCR amplification was per-
formed using a DNA thermal cycler (Catalys AG) in a
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50-L reaction volume containing 100 ng genomic
DNA, 1 polymerase mix (Eppendorf MasterMix
2.5x, Vaudaux-Eppendorf), and 0.5 mol/L of prim-
ers. Amplification was performed with an initial heat
activation step of 2 min at 95 °C followed by 35 cycles
of 95 °C for 45 s, 54 °C for 45 s, and 72 °C for 90 s and
then an extension step at 72 °C for 10 min. The ampli-
fied DNA product was sequenced using the same prim-
ers with a BigDye Terminator Cycle Sequencing Kit
(Applied Biosystems).
HIGH-RESOLUTION MS
Ion Trap and Fourier Transform Ion Cyclotron Reso-
nance MS was performed on an LTQ-FT mass spec-
trometer (Thermo Electron) using the NanoMate™
100 with ESI Chip Technology (Advion Biosciences).
The AGC target values were set to 7  105 for full scan
mode. A resolving power of 200 000 at 400 m/z was
used in acquisition of MS spectra, and 1 scan consisted
of 40 microscans. Hb samples were diluted 1:150 in
methanol-water (50:50 by volume) containing 0.2%
formic acid. A sample volume of 15 L was delivered to
the MS using the NanoMate™ 100 system. A Nano-
Mate high-density ESI chip was used as static nanoelec-
trospray emitter, providing stable spray conditions.
Voltages of 1.3–1.6 kV were applied to the chip through
the NanoMate power supply, whereas the mass spec-
trometer source voltage was set to 0. Samples were
infused using nitrogen gas at a pressure of 4000 Pa
(0.6 psi).
Results
DATABASE EVALUATION AND CALCULATIONS
To obtain the proportion of detected vs not yet de-
tected variants, we calculated, on the basis of the DNA,
every possible protein variant (only single-point muta-
tions in the exons leading to a single amino acid sub-
stitution) of the - and -globin chains. The results are
summarized in Fig. 1 and in Tables 1 (-chain) and 2
(-chain) in the Data Supplement that accompanies
theonlineversionofthisarticleathttp://www.clinchem.
org/content/vol53/issue12. The -chain with 141
amino acids gives rise to a total of 1269 DNA variants.
Because of the degenerated DNA code, 834 different
protein variants are possible. To date (cutoff date: July
19, 2007), 295 -variants (35.4%) are known. The eval-
uation of the -chain revealed 861 possible protein
variants (1314 DNA variants), of which 438 have been
observed (50.9%). Taking the - and -variants to-
gether, 43.2% of the possible variants have been de-
tected and 962 variants (56.8%) have not (Fig. 1A).
To assess whether an Hb variant should be detect-
able with electrophoretic or chromatographic meth-
ods, we calculated the pI (19 ) and the hydrophobicity
indices (20 ) of all Hb - and -variants (see Tables 1
and 2 in the online Data Supplement). pI differences of
0.050 units were considered as charge-difference
variants. Calculations revealed 290 possible -variants
with a charge difference. Currently, 173 (59.7%) have
been detected (Fig. 1B). On the other hand, only 122 of
544 neutral variants (22.4%) are known (Fig. 1C). In
the -chain, 253 of 335 (75.5%) possible charge differ-
ence variants have been found, and only 185 of the 526
possible neutral variants (35.2%) have been detected.
Overall, in 763 of 962 undetected variants we calculated
a pI-shift of 0.050 units. For these variants we would
expect no differences in electrophoretic mobilities.
To evaluate whether the calculated pI change is a
useful predictive parameter for the detectability in elec-
trophoretic or chromatographic methods, we analyzed
the entries of the known - and -variants in the Hb-
Var database and compared the information given in
the “Electrophoresis” and “Chromatography” sections
with the calculated pIs. In cellulose acetate electro-
phoresis and anion-exchange HPLC, the calculated pI
change predicted correctly a mobility difference in ap-
proximately 85% and 90% of all variants, respectively,
and in cation-exchange HPLC and IEF, the calculated
pI difference gave a correct prediction in 70% and 63%
of the variants, respectively.
Considering these factors, we would expect that
approximately 670 and 710 of the 962 not-yet-detected
variants are silent in cellulose acetate electrophoresis
and anion-exchange HPLC, respectively. Approxi-
mately 590 and 550 variants would be expected to be
silent in cation-exchange HPLC and IEF.
We also calculated the hydrophobicity values for
each variant, and a difference of 0.010 units was con-
sidered as a hydrophobicity change; 41.2% of the hy-
drophobicity change variants and 45.0% of the non-
change - and -variants have been detected.
Evaluation of the HbVar database entries revealed that
the hydrophobicity difference correctly predicts the
detectability in RP HPLC in 62% of the variants. We
therefore concluded that the calculated hydrophobic-
ity values are inadequately predictive parameters.
Furthermore, calculations of the mass differences
of all variants revealed that from the 962 currently un-
detected - and -variants, 92.0% (885 variants)
would be detectable with MS. Mass differences of the
globin chains of 6 Da are detectable with conven-
tional mass spectrometers.
Evaluation of the number of substitutions of the
- and -chain revealed that some of the most fre-
quently possible variants were rarely found, such as in
the -chain Leu3Gln (15 possible variants, 0 de-
tected) and Ala3Ser (21, 2), or in the -chain
Ala3Ser (15, 1) and Ala3Gly (15, 2). On the other
hand, some substitutions are frequently found, such as
MS in Hb Analysis
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His3Arg (10, 8) or Lys3Asn (11, 11) in the -chain
or Ala3Asp (14, 13) and Gly3Asp (12, 12) in the
-chain. A complete list of all substitutions is given in
Table 3 in the online Data Supplement.
LYSATE ANALYSES
Among the 2105 samples analyzed with cation-ex-
change HPLC (PolyCAT A column), RP HPLC, and
ESI or MALDI-TOF MS in our pediatric test center
during 5 years, 443 samples were found to be abnormal
owing to variant Hbs, thalassemias, or increased minor
fractions (samples with increased HbF excluded; Table
1). We found 4 chromatographically silent samples
with the variant Hb Riccarton (2 unrelated patients)
and 2 new variants: Hb Zurich-Hottingen and Hb Zu-
rich-Langstrasse (1 patient each). One patient with Hb
Malay was identified with cation-exchange HPLC to
have -thalassemia, and MS revealed the mutation in
the -chain. Two variants, Hb Hamilton and Hb City
of Hope (2 patients), were silent in PolyCAT A HPLC
but detected with RP HPLC and MS. On the other
hand, the following variants were not detectable with
MS: Hb C, D, E, E-Saskatoon, O-Arab, Lepore–Bos-
ton–Washington, and Schlierbach. Furthermore, the
thalassemias and Hb H/Barts are not detectable with
MS. Increased concentrations of HbA1c were detect-
able only when this variant consisted of more than
10%–15% of total Hb.
In MALDI-TOF MS, the experimental precision of
the mass measurement of the -chain [MH] was
determined to be 0.005% (CV; n  61; mean
15 869.110 Da; range 15 867.991–15 870.274 Da).
The ESI MS precision was comparable to the
MALDI-precision.
Fig. 1. Evaluation of all possible and detected protein variants (cutoff date: July 19, 2007; only single point
mutations are regarded).
A total of 834 variants of the -chain, 861 variants of the -chain, and 1695 of both chains are possible. A shows the numbers
of all possible variants, whereas in B and C, the number of variants differentiated according to their calculated charge are
shown. Variants with pI differences of 0.050 units were considered as charge-difference variants.
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IDENTIFICATION OF Hb ZURICH– HOTTINGEN AND Hb
ZURICH-LANGSTRASSE
During this study, 2 new chromatographically silent
Hb variants, Hb Zurich-Hottingen (24 ) and Hb Zu-
rich-Langstrasse, were detected. Both showed no ab-
normalities as analyzed by cation-exchange HPLC, RP
HPLC, or IEF. Hb Zurich-Langstrasse was detected in
an 83-year-old woman who was hematologically
asymptomatic. Her erythrocyte indices were as follows:
Hb, 118 g/L; erythrocytes, 4.0  1012/L; hematocrit,
0.37 L/L; mean cell volume, 89 fL; mean cell Hb, 30 pg.
HbA2 was 2.5% and HbF was 0.7%. The P50 (O2) was
not determined. Fig. 2 shows the MALDI-TOF mass
spectrum of the globins in Hb Zurich-Langstrasse.
Table 1. Results of lysate analyses.
Samples
Number
of
samples
Detectable
with cation-
exchange
HPLC
Detectable
with RP HPLC
Detectable
with MS
Total 2105
Normal 1578
Increased HbF 84
Abnormal 443
Variants
Hb S (6Glu3Val; 75 het.)a 137 Yes Yes Yes
Hb S/C 7 Yes Yes Only Hb S
Hb S/D 1 Yes Yes Only Hb S
Hb S/O-Arab ( 121Glu3Lys) 1 Yes Yes Only Hb S
Hb S/La Desirade ( 129Ala3Val) 1 Yes Yes Yes
Hb S/G-Philadelphia ( 68Asn3Lys)  -thal. 1 As Hb S/C Yes Yes
Hb C ( 6Glu3Lys; all het.) 10 Yes Yes No
Hb D ( 121Glu3Gln; all het.) 4 Yes Yes No
Hb K-Ibadan ( 46Gly3Glu)  -thal. 1 Yes Only Hb K-Ibadan Yes
Hb E ( 26Glu3Lys; 23 het.) 30 Yes Yes No
Hb E Saskatoon ( 22Glu3Lys) 1 Yes Yes No
Hb E /-thal. 1 Yes Only Hb E No
Hb Lepore-Boston-Washington (- hybrid; all het.) 13 Yes Yes No
Hb Schlierbach ( 108Asn3Ile) 5 Yes Yes No
Hb G-Philadelphia ( 68Asn3Lys) 2 Yes Yes Yes
Hb Frauenfeld ( 138Ser3Phe) 2 Yes Yes Yes
Hb Camperdown ( 104Arg3Ser) 1 Yes Yes Yes
Hb Malay ( 19Asn3Ser) 1 As -thal. Yes Yes
Hb Hamilton ( 11Val3Ile) 1 No Yes Yes
Hb City of Hope ( 69Gly3Ser) 2 No Yes Yes
Hb Zurich-Hottingen ( 9Asn3Ser) 1 No No Yes
Hb Zurich-Langstrasse ( 50Thr3Ser) 1 No No Yes
Hb Riccarton ( 51Gly3Ser) 2 No No Yes
Thalassemias and elevated minor Hb fractions
-Thal. major 16 Yes No No
-Thal. minor 186 Yes No No
HbA1c elevated (PTM) 13 Yes No Partly
b
Hb Barts (4)/Hb H (4) 2 Yes No No
a Het., heterozygous; PTM, posttranslational modification; thal., thalassemia.
b If HbA1c  10%–15%.
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It exhibits a broad signal containing 2 barely resolved
peaks corresponding to the normal - and the mutated
x-chain with a mass difference of 14 Da. In the inset
(Fig. 2), the DNA analysis of the -gene is presented.
It shows a heterozygous ACT3TCT mutation at
codon 50, resulting in a Thr3Ser substitution in the
-chain.
HIGH-RESOLUTION MS
To elucidate whether high-resolution MS enables de-
tection of variants with low mass differences (2 Da),
we analyzed a control sample, a heterozygous Hb D
sample, an Hb Lepore–Boston–Washington sample,
and an Hb Malmo¨ sample. The high-resolution MS of
m/z  934 (corresponding to the 17-fold protonated
-chain) are shown in Fig. 3. The resolution was
200 000 at 400 m/z, indicating that differences of 1 Da
are completely separated, and the different signals cor-
respond to the isotopic pattern of the -chain. Fig. 3A
shows the MS of the control sample with a normal
-chain, and Fig. 3B shows the MS of the Hb A/D sam-
ple, where the molecular mass of the D-chain is 1 Da
less owing to the 121Glu3Gln substitution. Fig. 3C and
3D exhibit the signals of the -chain in heterozygous
Hb Lepore–Boston–Washington (Lepore-chain has a
molecular mass shift of 	2 Da compared with the nor-
mal -chain) and of a patient heterozygous for Hb
Malmo¨ (mass shift 	9 Da due to the 97His3Gln sub-
stitution), respectively. The mass spectra in Fig. 3, A–C,
are not distinguishable, whereas in Fig. 3D 2 -chains
are clearly detectable.
Discussion
This study was initiated by the observation that the
predominant Hb variants listed in the globin gene
server (HbVar) database are charge-difference vari-
ants, a feature attributable to historical and method-
ological reasons and clearly demonstrated by the eval-
uation of the number of amino acid substitutions in the
- and -chain (see Table 3 in the online Data Supple-
ment). The majority of the frequently detected substi-
tutions are charge-difference substitutions. Calcula-
tion of the pIs (see Tables 1 and 2 in the online Data
Supplement) revealed that two-thirds of the possible
charge-difference variants are detected, whereas 30%
Fig. 2. MALDI-TOF MS of Hb Zurich-Langstrasse.
The spectrum shows 3 intense peaks corresponding to the
wild-type -chain (15 126 Da) and -chain (15 868 Da)
and the variant x-chain (15 854 Da). The mass difference
of 14 Da is due to the Thr3Ser substitution in the -chain.
Peaks marked with an asterisk correspond to matrix ad-
ducts. The inset shows the DNA analysis of the -gene
using the forward primer. The mutation site (ACT3TCT at
codon 50) is marked with an arrow.
Fig. 3. High-resolution mass spectra of the 17-fold
protonated -chain ([17H]17) of a control ly-
sate sample (A), a heterozygous Hb A/D sample (B), a
heterozygous Hb Lepore–Boston–Washington sample
(C), and a heterozygous Hb Malmo¨ sample (D).
The resolution was 200 000 at 400 m/z; therefore, a com-
pletely resolved isotopic pattern of the signals was
obtained.
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of the neutral variants were found to date (Fig. 1).
However, a calculated pI-shift does not necessarily re-
sult in a different electrophoretic or chromatographic
mobility of the variant. It must be considered that the
3-dimensional structure of the globins is determined
principally by the residues that form the interhelical
and helix-heme packings (25 ), and substitutions in
these sites may lead to conformational changes in the
proteins. The substitution effect also depends on the
3-dimensional position, viz. internal or external. For
example, the -variant Hb Sun Prairie (130Ala3Pro) is
silent in IEF, whereas Hb Fontainebleu (21Ala3Pro) is
detectable. The substituted amino acid is internal in Hb
Sun Prairie and external in Hb Fontainebleu (7 ). As a
very simple model, the calculation of the pI-shifts does
not consider conformational changes that might alter
the mobility. Therefore, mutations leading to a distinct
conformational change can diverge from the predicted
behavior. Furthermore, the model cannot predict reli-
ably unstable variants.
Nevertheless, pI calculations and the evaluation of
the method-specific detectability allow the prediction
of the number of the currently undetected, silent vari-
ants. We estimate that from the undetected 962 vari-
ants (Fig. 1A) a large proportion is silent with the most
common methods, e.g., approximately 590 variants
with cation-exchange HPLC or 670 variants with cellu-
lose-acetate electrophoresis. Although this is only a
rough estimate and may diverge in practice, we con-
clude that other methods that are not based on electro-
phoretic or chromatographic mobility should be ap-
plied in Hb variant analysis. Therefore, we suggest MS
as a supplementary method. ESI and MALDI-TOF MS
are methods that enable the detection of variants when
the mass difference between the abnormal and the
wild-type globin chains exceeds 6 Da. As calculated
in this study, MS methods would be able to detect 92%
of the undetected variants (885 of 962 variants).
Experimentally, we investigated whether we miss
neutral variants when using only chromatographic
methods (cation-exchange and RP HPLC). Indeed,
with additional MS analysis of all lysate samples during
a period of 5 years, we detected 2 new variants, Hb
Zurich-Hottingen and Hb Zurich-Langstrasse (Fig. 2).
Neither variant had a clinical impact. Furthermore, 2
samples with Hb Riccarton were detected. These neu-
tral variants are exclusively found by MS and are chro-
matographically silent (see Table 1). In an Hb Malay
sample, only the MS analysis revealed the variant
-chain, whereas in cation-exchange HPLC this sam-
ple was identified as a -thalassemia. Recapitulating,
we would have missed 4 of 2105 samples (0.2%) or 1%
of the abnormal samples without the use of MS
analysis.
In this study, we applied the 2 most important MS
techniques for protein analysis, ESI MS and MALDI-
TOF MS. Our conventional instruments would allow
the detection of variants with mass differences 6 Da
and showed comparable mass resolution. In ESI MS,
the sample preparation is very simple and requires only
the dilution of the lysate sample. In contrast, in the
MALDI-TOF MS approach, the lysate sample must
also be diluted and then prepared according to the
overlayer method as described in Materials and Meth-
ods, but the mass analysis of the globin chains is very
fast and requires only a few seconds per sample.
Two important drawbacks of the MS methods
should be mentioned. First, its insufficient resolution
prevents the detection of Hb mutations with small
mass differences of the globin chains. The precision of
normal low-resolution mass measurements was insuf-
ficient to distinguish the wild-type -chain from sev-
eral -chain variants, such as Hb C, D, or E. As shown
in Fig. 3, owing to the isotopic pattern, even high-res-
olution MS did not separate globin chains that differed
only in 1 or 2 Da from the normal chains. This result
confirms the statement of Rai et al. (26 ) that high res-
olution per se does not appear to offer a solution. Fur-
thermore, this result indicates that modestly priced in-
struments are just as useful in Hb analysis. Two intact
globin chains are not observed as separate entities in
MS unless their masses differ from one another by
more than 6 Da (27 ).
Second, MS as described here is only a qualitative
technique, and in particular, minor Hb fractions such
as HbA1C or HbA2, which are important for diagnosis
of diabetes mellitus or thalassemias, respectively, can-
not be quantified.
Nevertheless, MS allows the detection of electro-
phoretically or chromatographically silent Hb variants
and complements traditional techniques. Therefore,
we consider MS an indispensable tool that contributes
significantly to improved sensitivity in Hb analysis.
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Analysis of Minor Hemoglobins by Matrix-Assisted
Laser Desorption/Ionization Time-of-Flight
Mass Spectrometry
Karin Zurbriggen,1 Markus Schmugge,1 Marlis Schmid,1 Silke Durka,2
Peter Kleinert,2 Thomas Kuster,2 Claus W. Heizmann,2 and Heinz Troxler2*
Background: Hemoglobin (Hb) heterogeneity arises
mainly from posttranslational modifications of the glo-
bin chains, and cation-exchange chromatography re-
veals falsely increased concentrations of some minor
Hbs in the presence of abnormal Hbs. Here we describe
a method for identification of the globin chains and
their posttranslational modifications contained in the
Hb fractions.
Methods: We used cation-exchange HPLC (PolyCAT A
column) for separation of Hb fractions and matrix-
assisted laser desorption/ionization time-of-flight mass
spectrometry (MALDI-TOF MS) for analysis of the
separated globin chains. Globin chains were identified
by their molecular masses. Posttranslational modifica-
tions of globin chains were identified by digestion of
the proteins with endoproteinase V8 before MALDI-
TOF MS of the resulting peptides.
Results: Analysis of the HbA2 fractions of patients with
HbS revealed 4 different globin chains. We found, in
addition to the expected - and -chains, the carbamy-
lated - and the S-chains. Additionally, we analyzed
HbH, Hb Barts, HbA1b, pre-HbA1c, HbA1c, HbF1, HbF,
HbA1d3a, HbA1d3b, HbA2, and HbC1 fractions from con-
trol and pathologic blood samples. We identified sev-
eral posttranslational modifications of the globin
chains, such as pyruvatization, glycation, acetylation,
carbamylation, and acetaldehyde adduct formation.
Conclusions: The native and posttranslationally modi-
fied globin chains in minor and major Hbs are unam-
biguously identified by MALDI-TOF MS. A minor Hb
containing the carbamylated - and the S-chain elutes
at the same time as normal HbA2 (22) and thus leads to
falsely increased HbA2 values in patients with HbS
when blood is analyzed with PolyCAT A chromato-
graphy.
© 2005 American Association for Clinical Chemistry
Major and minor hemoglobin (Hb)3 components occur in
erythrocytes. Examples of major Hb components are
HbA, a tetramer consisting of 2 - and 2 -globin chains
(22), which is predominant after childhood and during
adult life, or HbF (22), which is the main Hb during fetal
development. HbF decreases rapidly after birth and be-
comes a minor Hb. During embryonic development, tet-
ramers of - and -chains in combination with - and
-chains are the predominant Hbs. Hb Gower 1 (22), Hb
Gower 2 (22), and Hb Portland (22) serve as oxygen
carriers (1 ). The minor Hb species, designated HbA1a
through HbA1e according to their elution order in cation-
exchange HPLC (2 ), consist mainly of HbA1c (22
glyc),
HbA1d3, and HbA2 (22). HPLC analysis of hemolysates
of healthy human erythrocytes shows that HbA1c consti-
tutes 4.4%–5.2% of the total Hb (3 ), whereas HbA1d3 and
HbA2 account for 3.5% (4 ) and 2%–3% (5–8), respectively.
The heterogeneity of human Hb arises mainly from
posttranslational modifications, principally glycation (9 ).
Glycated Hbs, which are referred to in order of their
elution as HbA1a1, HbA1a2, HbA1b1 through HbA1b3, and
HbA1c, result from the nonenzymatic attachment of glu-
cose (in HbA1c), fructose 1,6-diphosphate (in HbA1a1), or
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glucose 6-phosphate (in HbA1a2) (9, 10). Furthermore, Hb
can be glycated at multiple sites, including the amino
terminus, as well as certain -amino groups (9 ). There is
no accurate information about the globin chains of
HbA1d1, HbA1d2, and HbA1e available in the literature.
Possibly, HbA1d1 contains a globin chain modified by
acetaldehyde (11 ). On the other hand, the well-studied
HbA1d3 is composed of at least 2 components, HbA1d3a
and HbA1d3b, containing a carbamylated (urea adduct)
-chain and a glycated minor Hb (4 ). Additionally, a
novel Hb–glutathione adduct, which is increased in pa-
tients with diabetes and elutes in the HbA1d3 fraction, has
been reported (12, 13).
Acetylation and Hb adducts of aspirin, vitamin C,
penicillin, and acetyl-CoA are additional posttranslational
modifications (14 ). Additionally, Hb adducts with pyru-
vic acid at the amino terminus of the -chain (in HbA1b)
(15 ) or glycoinositolphospholipid at the carboxy terminus
of the -chain (16 ) are known.
The exact quantification of minor Hbs has important
diagnostic implications. For example, HbA1c is a marker
for diabetes mellitus (1, 17); HbA1d3a and HbA1d3b are
increased in uremic and diabetic patients, respectively (4 );
and the controversial influence of Hb–acetaldehyde ad-
ducts on HbA1d3 in female heavy drinkers has been
reported (4, 11). HbF is increased in hereditary persis-
tence of fetal Hb, -thalassemia intermedia, -thalassemia
major, and specific drug treatments (18 ). Increased HbF is
known to inhibit the polymerization of HbS, and the
monitoring of HbF concentrations during the follow-up
and treatment of patients with sickle cell anemia is
mandatory. HbA2 is increased in -thalassemia and in
megaloblastic anemia (1 ) but is decreased in -thalasse-
mia, iron deficiency, and sideroblastic anemia (1, 18).
Quantification of minor Hbs requires precise and spe-
cific methods. A widely applied technique is cation-
exchange HPLC, which, however, is known to give falsely
increased HbA2 values in HbS carriers (5, 19–21). In HbD
patients, increased (22 ) as well as decreased (21, 23) HbA2
concentrations have been reported. Although incomplete
separation of HbA2 and HbD explains increased mea-
sured HbA2 concentrations (22 ), Suh et al. (19 ) suggested
that coelution of HbS adducts, including glycated HbS,
with HbA2 also contributes to increased measured HbA2
concentrations. Other common Hb analysis techniques
include isoelectric focusing, reversed-phase HPLC, and
capillary zone electrophoresis (7, 14).
Since the development of soft ionization techniques,
electrospray ionization and MALDI-TOF MS have pro-
vided precise, rapid, and reliable analysis of Hb compo-
nents. These techniques are well suited to detect globin
chain mutations and posttranslational modifications. To
date, however, MALDI-TOF MS has seen remarkably
little application to Hb analysis (24, 25) despite its advan-
tages, such as high sensitivity and short analysis times.
Because many of the -chain variants, including HbC,
D-Los Angeles, E, and O-Arab, exhibit mass shifts of only
1 Da, their analyses require high-resolution instruments.
In this study, we used MALDI-TOF MS to investigate
globin chains constituting different minor Hbs. We also
used this technique to elucidate the minor components in
erythrocyte lysates responsible for falsely increased HbA2
values in HbS patients.
Materials and Methods
blood samples
We analyzed a collection of anonymized human blood
specimens from a routine chromatography laboratory;
therefore, no ethics approval was required. Blood samples
had been collected with EDTA or heparin as anticoagu-
lant, stored at 4 °C, and generally analyzed within 24 h.
For the determination of HbA2 values, we used fresh
samples (Hb analysis with PolyCAT A HPLC is a routine
analysis of our hospital). In most cases, analysis was
performed within 24 h. For the isolation of different Hb
fractions, we used some fresh and some previously col-
lected samples (especially the blood samples from pa-
tients with rare diseases). HbA2 fractions were isolated
from fresh samples (in most cases not older than 24 h). We
prepared hemolysates for chromatographic analysis by
lysing washed erythrocytes in 1 mmol/L KCN.
Hb analysis with HPLC
We performed cation-exchange HPLC with a 200 
4.6-mm (i.d.) PolyCAT A column (LCC Engineering &
Trading GmbH) according to the method of Bisse´ et al.
(26 ) on a Shimadzu LC-2010C instrument. The HPLC
program included (a) a linear gradient from 15% to 65%
solvent B in 30 min; (b) a linear gradient from 65% to 100%
solvent B in 0.1 min; (c) an isocratic flow of 100% solvent
B for 6 min; (d) a linear gradient from 100% to 15% solvent
B in 0.1 min; and (e) an isocratic flow of 15% solvent B for
10 min [solvent A, 35 mmol/L Bis-Tris, 1.5 mmol/L KCN,
3 mmol/L NH4CH3COO (pH 6.67); solvent B, 35 mmol/L
Bis-Tris, 1.5 mmol/L KCN, 17 mmol/L NH4CH3COO, 150
mmol/L NaCH3COO (pH 7.0)]. We injected 3 L of
sample, monitored peaks at 414 nm, and collected frac-
tions of minor Hbs manually. We used WinSTAT® soft-
ware for statistical calculations.
sample concentration
We concentrated the isolated Hb fractions to a final
volume of 50 L with 5-kDa-cutoff Amicon® Ultra-4
Centrifugal Filter Devices (Millipore). Before mass spec-
trometric analysis, we further desalted 10 L of isolated
minor Hb samples with C18 ZipTips® (Millipore) and
eluted them with 3 L of 750 mL/L CH3CN in 1 mL/L
trifluoroacetic acid (TFA). We used 0.5 L of the desalted
sample for MALDI-TOF MS.
maldi-tof ms
To analyze globin chains, we used the autoflex system
(Bruker Daltonics) for MALDI-TOF MS. The mass reso-
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lution at 15 kDa was 750 (m/m). Isolated HPLC
fractions were analyzed by the overlayer method. We
applied a thin layer of sinapinic acid (saturated solution in
ethanol) to a ground-steel MALDI target. We then mixed
equal volumes of protein sample and a saturated sinap-
inic acid solution (in 330 mL/L CH3CN–1 mL/L TFA),
applied 0.5 L of the mixture to the thin layer, and dried
the target at room temperature. To analyze the globin
digests, we applied 0.5 L of the sample directly to a
600-m AnchorChipTM (Bruker Daltonics) target and
added, on top of the analyte solution, 1.1 L of a saturated
matrix solution consisting of -cyano-4-hydroxycinnamic
acid (in 330 mL/L CH3CN–1 mL/L TFA), diluted 1:10 in
ethanol–acetone (67:33 by volume). After drying the tar-
get at room temperature, we performed on-target wash-
ing with 2 L of 1 mL/L TFA.
protein digests
Globin chains were digested by adding 1 g of endopro-
teinase Glu-C (Boehringer Mannheim) or 0.2 g of trypsin
(Promega) and 20 L of digestion buffer (25 mmol/L
NH4HCO3, pH 7.8) to the lyophilized sample. The solu-
tion was incubated overnight at room temperature (Glu-C
digestion) or at 37 °C (trypsin digestion).
Results
PolyCAT A HPLC analysis of lysates
A typical PolyCAT A chromatogram of the erythrocyte
hemolysate prepared from blood of a healthy donor is
shown in Fig. 1A. In addition to the major HbA, a series of
minor Hbs are evident, of which the most intense are
HbA1c; HbA1d3 with its 2 components, HbA1d3a and
HbA1d3b; and HbA2. Other Hbs, such as HbA1a  b,
HbA1d1  2, and HbA1e, have lower intensities and are
only partly resolved. Shown in Fig. 1B is a PolyCAT A
chromatogram of the lysate from an individual heterozy-
gous for HbS. Typically, an intense peak corresponding to
HbS elutes at a retention time of 30 min. MALDI-TOF
analysis of the isolated fraction of HbS revealed 2 globin
chains, the -chain at 15 127 Da and the S-chain at 15 838
Da (Fig. 1B, inset), whereas the typical - and -chains
were detected in the HbA fraction (data not shown).
analysis of minor Hbs by MALDI-TOF MS
A selection of MALDI-TOF mass spectra of isolated
fractions containing separated minor Hbs is shown in Fig.
2. The peaks are assigned according to the expected
molecular masses of the globin chains. Table 1 summa-
rizes the globin chains detected in the different fractions.
As shown in Fig. 2A, the mass spectrum of a HbA1b
fraction isolated from a patient with glycogenose type I
includes peaks that correspond to the -chain (15 127 Da),
the pyruvic acid adduct of the -chain (15 938 Da), and
the latter’s decarboxylated form (15 894 Da). The mass
spectra in panels B and C of Fig. 2 correspond to the
globin chains in the pre-HbA1c and the HbA1c fractions,
with glycated - and -chains at molecular masses of
15 289 (Fig. 2B) and 16 030 Da (Fig. 2, B and C), respec-
tively. Analysis of the HbC1 fraction isolated from a
patient with HbC revealed a very similar mass spectrum
for HbA1c (data not shown). HbC1, a minor Hb eluting
slightly before HbC, contains the characteristic -chain
and a glycated C-chain that differs by only 1 Da from the
typical glycated -chain, glyc.
Shown in Fig. 2D are the globin chains that produce the
HbF1 peak, a minor Hb in samples with high HbF content.
The chains at 15 996 and 16 038 Da are assigned to the G-
and the acetylated G-chains, respectively, and both peaks
contain a shoulder representing the A- and acetylated
A-chains, respectively. Finally, the mass spectra of the
partly separated HbA1d3a (Fig. 2E) and HbA1d3b (Fig. 2F)
peaks exhibit several different globin chains at 15 127
(-chain), 15 868 (-chain), 15 170, and 15 894 Da. From
data reported in the literature, we concluded that the peak
at 15 170 Da corresponds to the carbamylated -chain
(urea adduct), whereas the peak at 15 894 Da is consistent
Fig. 1. PolyCAT A HPLC analysis of erythrocyte lysates from an adult
control (A) and a patient with HbS (B).
(A), minor Hbs that are typically detectable in lysates from healthy adult controls.
(B, inset), the isolated HbS fraction was investigated with MALDI-TOF MS. Shown
are the - and S-globin chains found in the isolated HbS fraction at 15 127 and
15 838 Da, respectively.
Clinical Chemistry 51, No. 6, 2005 991
25
with an acetaldehyde adduct of the -chain. To confirm
these assumptions, we digested the globin chains in the
fractions with endoproteinase Glu-C or trypsin. After
subsequent MALDI-TOF MS analyses of the peptides, we
detected the urea adduct with the N-terminal peptide of
the -chain (data not shown). The tryptic digest of the
peak at 15 894 Da, however, contained no acetaldehyde
adduct with the N-terminal peptide of the -chain. We
conclude that a site other than the amino terminus must
therefore form an adduct with acetaldehyde.
HbA2 values determined with PolyCAT A HPLC
To investigate the reasons for increased HbA2 concentra-
tions in erythrocyte lysates of HbS carriers, we analyzed
Fig. 2. Selection of minor Hbs analyzed by MALDI-TOF MS.
The HbA1b fraction (A) was collected from a patient with glycogen storage disease type I; the pre-HbA1c and HbA1c fractions (B and C) are from a patient with diabetes;
the HbF1 fraction (D) is from a newborn; and the HbA1d3a and HbA1d3b (E and F) fractions are from a control sample. , peaks corresponding to matrix adducts.
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32 samples from different heterozygous HbS patients, 42
samples from homozygous HbS patients, and 200 samples
from unaffected controls by cation-exchange HPLC (Poly-
CAT A). We also analyzed a second control group that
included 47 samples from patients with -thalassemia
minor (Table 2). Compared with the control samples, the
HbA2 concentrations in HbS patients (homozygous and
heterozygous) were statistically significantly increased (P
0.0001, Student t-test). In homozygous and heterozy-
gous HbS patients, the concentrations were 4.95% and
4.22% of total Hb, respectively. These concentrations are
clearly increased relative to the concentration (2.68%)
measured in the control samples. The HbA2 concentration
in homozygous HbS patients (4.95%) approached that of
-thalassemia patients (5.35%).
elucidation of unknown minor Hb
We assumed that a minor Hb coeluted with HbA2 and
thus falsely increased HbA2 values in patients with sickle
cell anemia. We therefore isolated the HbA2 fractions of 12
HbS samples (3 heterozygotes and 9 homozygotes) and 2
-thalassemia samples. The MALDI-TOF mass spectra of
the HbA2 fractions with 2 intensive peaks at 15 127 and
15 925 Da correspond to the normal - and -chains,
respectively (Fig. 3). Both -thalassemia samples gave
similar spectra. On the other hand, the MALDI-TOF mass
spectrum of the HbA2 fraction isolated from a patient
with HbS included 4 different globin chains with masses
at 15 127, 15 170, 15 838, and 15 925 Da (Fig. 3B). All HbA2
fractions isolated from 9 HbS samples gave similar
MALDI-TOF mass spectra (data not shown). To exclude
artifacts, we purified an isolated HbA2 fraction of a
heterozygous HbS carrier 3 times by cation-exchange
chromatography, and MALDI-TOF analysis revealed the
peak at 15 838 Da. As in Fig. 3A, the peaks at 15 127 and
15 925 Da were assigned to the normal - and -chains.
The peak at 15 838 Da, moreover, corresponds to the
S-chain, whereas the peak at 15 170 Da is consistent with
a posttranslationally modified -chain. Considering the
results obtained for the HbA1d3a fraction, we assumed
that carbamylation of the -chain accounted for the mass
shift of 43 Da compared with the normal -chain. With
digestion of the HbA2 fraction by endoproteinase Glu-C
and subsequent MALDI-TOF MS analysis of the resulting
peptides, we confirmed this assumption (data not shown).
The 15 170-Da globin chain corresponds to the N-termi-
nal–carbamylated -chain.
Discussion
Traditional methods for Hb analysis, such as chromatog-
raphy and electrophoresis, reveal only symmetric Hb
tetramers because of the rapid dissociation of tetramers to
dimers relative to the separation time (27 ). We confirmed
this finding by analyzing a heterozygous HbS sample
(Fig. 1B). MALDI-TOF analysis of the isolated HbA and
HbS fractions revealed only globin chains of symmetric
Hbs,  (tetrameric structure, 22) and 
S (22
S), re-
Table 1. Major and minor Hbs and the detected globin chains.
Hb Elution in PolyCAT A HPLC, % B Globin chains detected by MALDI-TOF MS (mass in Da) Sample origin
HbH 18  (15 868) -Thalassemia
HbBarts 18 G (15 996); A (16 010) -Thalassemia
HbA1b 27  (15 127); 
pyr (15 938); pyr-CO2 (15 894) GSD-Ia
pre-HbA1c 30  (15 127); 
glyc (15 289); glyc (16 030) Diabetes
HbA1c 35  (15 127); 
glyc (16 030) Diabetes
HbF1 30  (15 127);
G (15 996); A (16 010, shoulder);
acet. G (16 038); acet. A (16 052, shoulder)
Newborn
HbF 37  (15 127); G (15 996); A (16 010) Newborn
HbA1d3a 45 
carb (15 170);  (15 127);  (15 868); ach (15 894) Control
-GSH (16 173) GSD-I
HbA1d3b 48  (15 127); 
glyc (15 289);  (15 868); ach (15 894) Control
HbA 52  (15 127);  (15 868) Control
HbA2 60  (15 127);  (15 925) Control
HbA2 60  (15 127); 
carb (15 170);  (15 925); S (15 838) HbS
HbS 100  (15 127); S (15 838) HbS
HbC1 100  (15 127); 
C, glyc (16 030)b HbC
HbC 100  (15 127); C (15 868)b HbC
a GSD-I, glycogen storage disease type I; pyr, pyruvic acid adduct; pyr-CO2, decarboxylated pyruvic acid adduct; glyc, glycated; acet, acetylated; carb, carbamylated;
ach, acetaldehyde adduct; GSH, glutathione.
b Because of limited instrument mass resolution, the expected mass shift of 1 Da, compared with the normal glycated -chain, is not detectable with conventional
MALDI-TOF instruments.
Table 2. HbA2 concentrations in patients with HbS or
-thalassemia, and in control samples.
Samples n Mean (range), % of total Hb CV, %
Controls 200 2.68 (2.0–3.5) 11
-Thalassemia minor 47 5.35 (4.1–7.3) 13
HbS heterozygote 32 4.22 (3.6–5.1) 7.6
HbS homozygote 42 4.95 (3.1–7.0) 33
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spectively. We observed no peak for the expected asym-
metric tetramer 2
S, leading us to conclude that the
observed peaks in cation-exchange HPLC all correspond
to dimers and not to tetramers. The signals in a PolyCAT
A chromatogram therefore do not reflect the real tet-
rameric Hbs.
Use of MALDI-TOF MS to analyze desalted and con-
centrated minor Hb fractions allows measurement of the
globin chains that build the tetrameric structure of the Hb.
We applied our procedure to isolated Hbs detected in Hb
samples from healthy individuals and from patients with
various disorders that produce hemoglobin variants (Ta-
ble 1). The mass spectrum of the HbA1b fraction (Fig. 2A)
isolated from a patient with glycogenose type I is charac-
terized by 2 posttranslationally modified -chains, of
which the peak with mass 15 938 Da represents the
pyruvated -chain built by nonenzymatic condensation of
pyruvic acid with the -chain amino terminus (1 ). Addi-
tionally, the decarboxylated form of the pyruvated
-chain (15 894 Da) is present. Pyruvate adducts corre-
spond well with increased pyruvate concentrations in
patients with glycogen storage disease type I.
The mass spectrum of a pre-HbA1c fraction that elutes
slightly before HbA1c (at 30% solvent B), in a sample from
a patient with diabetes, is shown in Fig. 2B. In addition to
the normal -chain, the glycated - and -chains are
detectable at 15 289 and 16 030 Da, respectively. We
conclude that pre-HbA1c must contain a Hb with at least
1 glycated -chain. On the other hand, the HbA1c fraction
(Fig. 2C), an important diabetes marker, contains the
expected -chain and glyc-chain, leading to the known
22
glyc structure. The analysis of a HbC1 fraction revealed
a mass spectrum very similar to that for a normal -chain
and a glycated C-chain, which differs by only 1 Da from
glycated -chain (data not shown). In diabetic patients
with HbC, therefore, the minor HbC1 peak represents a
dimer C, glyc and must be included in the quantification
of glycated Hbs.
The mass spectrum of the HbF1 fraction, an Hb that
appears with high HbF concentrations, exhibits the acety-
lated G- and A-chains (shoulder of the peak; Fig. 2D).
Acetylation as a posttranslational modification occurs
frequently in human proteins. Native Hb, however, is not
N-terminally acetylated (except for -globin) because the
N-terminal valine of -, -, and -globins inhibits acety-
lation (28 ). Both nearly identical -globin chains are
expressed by the G-globin and A-globin genes. In hu-
mans at the age of 5 months, A-globin chains become
predominant (8 ). Finally, HbF1 and HbF (22) are in-
creased in patients with homozygous HbS on hydroxy-
urea treatment. This drug increases, by as yet unclear
processes, the HbF concentration, which inhibits the po-
lymerization of HbS, thereby reducing vaso-occlusive
events (29 ).
HbA1d3a (Fig. 2E) and HbA1d3b (Fig. 2F), which eluted
at 45% and 48% solvent B, respectively, could not be
separated completely. Of the 4 intense peaks detected in
the HbA1d3a fraction, the peak at 15 170 Da corresponds to
the carbamylated -chain, and the peak at 15 868 Da is
consistent with the normal -chain. We attribute the
chains with masses of 15 127 and 15 894 Da to the partly
overlapping HbA1d3b fraction. HbA1d3a is reported to be
significantly higher in uremic than in nonuremic patients
(4 ). These observations correspond well with our findings
of a carbamylated -chain (adduct of urea to the amino
terminus of the -chain); on the other hand, the HbA1d3b
fraction exhibited 3 major chains, the normal - and
-chains and a modified -chain at 15 894 Da (Fig. 2F).
The characteristic - and -chains in this fraction probably
arise partly from overlapping of the highly intense HbA
peak. HbA1d3 is reported to be increased in female heavy
drinkers and in alcoholic individuals, but the increase is
not statistically significant (11 ). The first metabolite of
ethanol, acetaldehyde, is known to form adducts with
Hbs (10 ). We therefore assume that the peak at mass
15 894 Da could be attributed to the -chain adduct with
acetaldehyde (ach), which corresponds well with the
observed mass shift of 26 Da. Occasionally, in patients
with diabetes, the glutathionylated -chain at mass 16 173
Fig. 3. MALDI-TOF mass spectra of isolated HbA2 fraction from a
-thalassemia patient (A) and from a HbS patient (B).
The carb- and S-globin chains are found only in patients with HbS (homo- and
heterozygotes). , peaks corresponding to matrix adducts.
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Da is also detected (data not shown), a finding consistent
with other reports (4, 12, 13) of increased glutathionylated
-chain concentrations that lead to increased HbA1d3b
concentrations. Additionally, a minor peak corresponding
to a glycated -chain (15 289 Da) was detected. Assuming
a dimeric structure of PolyCAT A-separated compounds,
we conclude that this fraction must contain at least 2
different Hbs, namely ach and glyc.
The HbA1d fraction is reported to increase slowly with
hemolysate age (30 ). Possibly, carbamylation plays a
crucial role in Hb aging. Elucidation of the aging process,
however, will require further studies.
HbBarts (4) and HbH (4), 2 Hbs consisting of only
one type of globin chain, are markers for -thalassemia.
These Hbs elute at 18% solvent B when PolyCAT A HPLC
is used. Analysis of the isolated fraction of HbBarts
revealed only 1 intense peak at 16 010 Da, corresponding
to the -chain (data not shown).
We also tried to analyze other fractions containing
minor Hbs, such as HbA1a, HbA1d1  2, and HbA1e. Low
concentrations and strong overlapping of intense Hbs,
however, prevented successful analysis of these compo-
nents. To identify these minor Hbs, a promising strategy
is the analysis of disease samples that exhibit increased
minor Hbs as observed in the HbA1b peak isolated from a
patient with glycogenose type 1.
We also used analysis of minor Hbs by MALDI-TOF
MS to investigate HbA2 in HbS carriers. It is well estab-
lished that HbA2 is increased in the presence of the
-chain variant HbS (5, 19–21) when analyzed by chro-
matographic methods. Additionally, HbA2 is reported to
inhibit polymerization of deoxy-sickle hemoglobin (HbS)
in vitro (31 ). In this study, we analyzed samples from HbS
carriers and compared their HbA2 values with the values
for controls and confirmed -thalassemia carriers. The
HbA2 concentrations of the HbS patients were clearly
increased compared with those of the controls (Table 2)
and agree with those of Shokrani et al. (5 ). In 1996, Suh et
al. (19 ) undertook a study to investigate the increased
HbA2 concentrations in greater detail. They assumed that
coelution of HbS adducts, including glycated HbS with
HbA2 on HPLC, was responsible for the increased HbA2
value. They were not able, however, to elucidate the
supposed coeluting Hb component.
To investigate this proposed HbS adduct, we analyzed
isolated HbA2 fractions of HbS and -thalassemia sam-
ples with MALDI-TOF MS. In the HbA2 fraction of a
patient with -thalassemia (without HbS), the expected -
and -chains (Fig. 3A) were present. The different signal
intensities of the 2 peaks resulted from distinct mass
spectrometric signal responses and not from various
amounts of the globin chains. In contrast to the spectrum
of the -thalassemia sample, we found in all investigated
HbS samples additional globin chains at 15 170 and 15 838
Da (Fig. 3B). The 15 838-Da globin chain could easily be
assigned to the variant -chain, S. The presence of the
S-chain in the HbA2 fraction is explained by incomplete
separation of an intense HbS peak and the HbA2 peak
when analyzed with cation-exchange HPLC. In heterozy-
gous HbS samples, we also detected the peak at 15 838 Da,
but we could separate the HbS peak and the bA2 peak
completely. We therefore conclude that the variant S-
chain is participating in coelution of the minor Hb with
HbA2.
The peak at 15 170 Da must be assigned to a posttrans-
lationally modified -chain. Considering the previously
found globin chains in HbA1d3a, we suspected that the
modification is carbamylation of the -chain. Mass spec-
trometric analysis of the peptides resulting from endopro-
teinase Glu-C digestion of the HbA2 fraction confirmed
this assumption (data not shown). From these results, we
conclude that the increase in HbA2 in patients with HbS
cannot be attributed to the presence of glycated S, as is
commonly accepted, but arises from coelution of the
minor Hb carbS with HbA2.
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In this study, we present a versatile new procedure for
the analysis of transferrin and its isoforms isolated
from human body fluids such as serum, plasma, and
cerebrospinal fluid. This method is based on a three-
step procedure: (i) isolation of transferrins using an-
ion-exchange chromatography with UV detection; (ii)
concentration of the transferrin fraction; (iii) detection
of the transferrins with liquid chromatography-elec-
trospray mass spectrometry. Pre-analytical sample
procedures can be omitted and no immunoaffinity
columns or transferrin-specific immunoassays were
used. Anticoagulants such as heparin, EDTA, citrate,
and oxalate do not interfere with our analysis. Accord-
ing to their respective molecular masses, up to ten dif-
ferent isoforms of transferrin could be identified in a
serum sample from a patient with a congenital disor-
der of glycosylation type Ia (CDG-Ia). The method was
successfully applied to different pathological samples
from patients with CDG-Ia, CDG-Ib, CDG-Ic, CDG-Ie,
CDG-If, and CDG-IIa. Additionally, samples from alco-
hol consumers that were found with turbidimetric im-
munoassay to contain increased levels of carbohy-
drate-deficient transferrin were analyzed. Clin Chem
Lab Med 2003; 41(12):1580–1588
Key words: Carbohydrate-deficient transferrin; Con-
genital disorders of glycosylation; Electrospray ioniza-
tion mass spectrometry; Glycosylation; Transferrin iso-
form.
Abbreviations: 1D PAGE, one-dimensional polyacryl-
amide electrophoresis; 2D PAGE, tow-dimensional
PAGE; CDG, congenital disorder(s) of glycosylation (for-
merly carbohydrate-deficient glycoprotein syndrome);
CDT, carbohydrate-deficient transferrin; CSF, cerebro-
spinal fluid; ER, endoplasmic reticulum; ESI-MS, electro-
spray ionization mass spectrometry; IEF, isoelectric fo-
cusing; MALDI-TOF, matrix-assisted laser desorption/
ionization-time-of-flight; PAGE, polyacrylamide gel elec-
trophoresis; pI, isoelectric point; RP-HPLC, reversed-
phase-high-performance liquid chromatography; SDS-
PAGE, sodium dodecylsulfate-polyacrylamide gel
electrophoresis; TIA, turbidimetric immunoassay; Trf,
transferrin.
Introduction
Evaluation of all proteins from the SWISS-PROT data-
base revealed that more than half of the naturally oc-
curring proteins are potentially N- or O-glycosylated.
Some 75% of all glycoproteins are N-linked, about 10%
O- as well as N-linked, and the rest solely O-linked (1).
Glycosylation of proteins involves a complex series of
enzymatic reactions, and this post-translational modifi-
cation is important for the proper folding of the newly
synthesized polypeptide chains. Inhibition of glycosy-
lation results in misfolded, aggregated proteins that af-
fect proper function (2). Variations of the glycan moi-
eties on glycoproteins lead to different glycoforms of
the protein and affect protein activity and function.
Several inherited diseases, such as I-cell disease, con-
genital disorders of glycosylation (CDG), leukocyte-ad-
hesion deficiency type II, Wiskott-Aldrich syndrome, or
glycoproteinoses are known, in which the diagnosis is
based on alterations in the oligosaccharide structure of
glycoproteins (3). Different methods used to analyze
isoforms of glycoproteins are described in (4). 
Transferrin (Trf) is one of the best characterized hu-
man glycoproteins. It consists of a single polypeptide
chain of 679 amino acids containing two N-linked gly-
can chains attached to Asn residues 413 and 611. Trf
contains an N-terminal (amino acids 1–336) and a
C-terminal (amino acids 337–679) globular domain.
Each domain contains a metal-binding site, but only
the C-terminal domain embodies the two N-glycosyla-
tion sites (5). Trf is the most important Fe3 + transport
protein in humans (6). Carbohydrate-deficient Trf (CDT)
plays an important role as a marker of chronic alcohol
abuse and of congenital disorders of glycosylation.
Overviews of disorders, in which increased levels of
CDT are observed, are shown in (6, 7). 
The micro-heterogeneity and the low amount of CDT
in the plasma of healthy controls require high sensitiv-
ity and specificity of the analysis (6). Routine laboratory
analysis of serum CDT requires separation of the dif-
ferent isoforms (CDT and non-CDT) of Trf. Most current
methods are charge-based separation procedures us-
ing anion-exchange chromatography or isoelectric fo-
cusing (IEF) with detection by various immunoassays,
*E-mail of the corresponding author: 
heinz.troxler@kispi.unizh.ch
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e.g., radioimmunoassay (RIA), turbidimetric immuno-
assay (TIA), or enzyme immunoassay (EIA). High-per-
formance liquid chromatography (HPLC) has also been
applied for the analysis of CDT (6, 8). The chromato-
graphic methods are less sensitive and less selective
compared to IEF. Therefore, IEF is used as the reference
method for serum Trf isoform analysis, where the Trf
isoforms are separated according to their characteristic
isoelectric points (pIs) (6). 
An alternative method for the analysis of the Trf iso-
forms is mass spectrometry. The soft ionization tech-
niques used in electrospray ionization mass spectrom-
etry (ESI-MS) and matrix-assisted laser desorption
ionization mass spectrometry (MALDI) enable the
analysis of even very large proteins, such as Trf with a
molecular mass of almost 80 kDa. In 1992, Wada et al.
(9) reported the analysis of different glycoforms from a
CDG patient using ESI-MS. In 1993, ESI-MS analysis of
Trf, purified by a one-step procedure from serum,
yielded a diagnosis of the CDG syndrome (10). Re-
cently, a fast method for the analysis of Trf from blood
spots was published (11), using a combination of on-
line immunoaffinity post-concentration ESI-MS in con-
junction with a blood spot cartridge for the determina-
tion of the human Trf glycoforms. Lacey et al. (12)
published a rapid method based on immunoaffinity liq-
uid chromatography and ESI-MS for the analysis of
serum Trf. With this method, the analysis time could be
reduced to less than 10 min. Peter et al. (5) analyzed
CDT with MALDI-TOF mass spectrometry.
In this work, we present a novel three-step proce-
dure for the analysis of Trf and its isoforms. In the first
step, the glycoproteins are separated from other
plasma proteins by anion-exchange chromatography
(UV detection). After SpeedVac concentration (second
step), the sample is analyzed with HPLC-ESI-MS (third
step). A small amount of plasma (30 µl) is used for the
determination of CDT and no pre-analytical proce-
dures, such as in vitro saturation of Trf with Fe3 +, are
necessary. We used common and less expensive weak
anion-exchange and C8-reversed-phase columns in-
stead of special affinity columns. We evaluated our
method with plasma and serum samples from healthy
controls, patients with CDG syndrome, cystic fibrosis,
and from excessive alcohol consumers. Finally, the ver-
satility of our method was demonstrated by analyzing
Trf from human cerebrospinal fluid (CSF).
Materials and Methods
Three-step procedure for analyzing transferrin isoforms 
1. Ion exchange chromatography 
Thirty µl of plasma or serum were diluted with 200 µl of sol-
vent A and subjected to anion-exchange HPLC using a separa-
tion column (Brownlee Aquapore AX-300, 4.6 × 100 mm,
PerkinElmer, Shelton, USA) with a guard column of the same
material (4.6 × 30 mm). Transferrins were separated from
other proteins using the following HPLC program: (i) isocratic
flow 100% solvent A for 5 min; (ii) linear gradient from 0% to
30% solvent B (v/v) in 10 min; (iii) isocratic flow 30% B for
5 min; (iv) linear gradient from 30% to 100% B in 1 min; (v) iso-
cratic flow 100% B for 14 min. HPLC was carried out on a Wa-
ters 625 LC system (Millipore, Milford, USA). The flow rate
was 1 ml/min, and peaks were detected by monitoring ab-
sorbance at 254 nm (Waters 484 detector). Solvents A and B
were 50 mM Tris pH 7.5 and 500 mM Tris pH 7.5, respectively.
2. Sample concentration
The Trf fraction (about 3 ml) was collected manually and re-
duced to less than 200 µl in a SpeedVac concentrator (Savant,
Farmingdale, USA). Alternatively, it can be concentrated with
Centricon YM-3 Filter Devices (Millipore, Bedford, USA). 
3. HPLC and mass spectrometric analyses
The concentrated Trf fraction was desalted on a C8 reversed-
phase HPLC column (Brownlee Aquapore RP-300,
2.1 × 100 mm, Perkin-Elmer, Shelton, USA). The protein was
eluted with the following HPLC program: (i) isocratic flow 5%
solvent B (v/v) for 5 min; (ii) linear gradient from 5% to 50% sol-
vent B in 5 min; (iii) linear gradient from 50% to 60% solvent B
in 13 min; (iv) linear gradient from 60% to 90% B in 1 min; (v)
isocratic flow 90% B for 10 min. Solvents A and B were 0.1% tri-
fluoroacetic acid and 0.07% trifluoroacetic acid in 80% acetoni-
trile, respectively. The flow rate was 100 µl/min. The HPLC sys-
tem (Applied Biosystems 140B, Foster City, USA) was directly
connected to a Perkin-Elmer Sciex API 365 LC/MS/MS system
(Foster City, USA), and the flow split was 1:10. Mass spectra
were acquired in the range of m/z 1500 to 3000, with step size
0.1 (6 s per scan). Molecular mass determination accuracy was
estimated to be around 15 Da.
Gel electrophoresis
One-dimensional sodium dodecylsulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) was performed using standard
methods (Laemmli buffer system, 13% T, 5% C) on a Bio-Rad
Mini-Protean 3 system (Bio-Rad, Hercules, USA). Proteins
were visualized by silver staining (13). Protein concentrations
in the fractions were determined using Bio-Rad protein assay.
Trf standard was purchased from Sigma (St. Louis, USA).
Two-dimensional SDS-PAGE was performed according to
standard protocols (14) using IPG strips with a linear pH gra-
dient of 5–8 (ReadyStrip, Bio-Rad, Hercules, USA). The sam-
ple was applied by cup loading (at the cathode) and IEF was
carried out on an IPGphor electrophoresis unit (Amersham-
Pharmacia, Uppsala, Sweden). Focusing was started with a
linear gradient from 300 to 3500 V in 3 hours followed by
3 hours at constant 3500 V. Then the voltage was increased
linearly to 5000 V in 30 min. Focusing was stopped after reach-
ing a cumulative 100 kiloVolt-hours (100 kVh). The second di-
mension was performed on a Bio-Rad Protean II xi system. Gel
dimensions were 20 × 16 × 0.15 cm (13% T, 5% C). Proteins
were visualized by silver staining (15). 
Iron saturation 
Trf was saturated with iron by adding 1 µl of 10 mM FeCl3 to 50 µl
of serum. Then 1.3 µl of 500 mM NaHCO3 was added. The mix-
ture was shaken vigorously and incubated at 4 °C overnight. 
Isoelectric focusing (IEF)
IEF of serum samples was carried out according to Stibler (16)
and de Jong et al. (17), modified as follows: 2 µl FeCl3 (10 mM)
and 2 µl NaHCO3 (0.5 M) were added to 50 µl serum and left at
room temperature for 30 min. Immobiline™ Dry Plate pH 4–7
(Amersham Biosciences, Uppsala, Sweden) IEF plates were
prepared in 17% glycerol according to the manufacturer’s
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guideline and the middle section (gradient range ca. pH 5 to 6)
was cut out to fit into the IEF PhastSystem (Amersham Bio-
sciences, Uppsala, Sweden). Before loading, 2 µl of sample
was mixed with 4 µl of 0.2% Triton X-100 and 0.5 µl was loaded
onto the gel, cooled at 10 °C. IEF settings were: 450 V, 50.0 mA,
6.0 W to 90 Vh, then 2000 V, 50.0 mA, 6.0 W to 1500 Vh. After
the run, 100 µl of Anti-Human Transferrin (Dako, Glostrup,
Denmark) was layered on the gel surface and left for 45 to
60 min for immunoprecipitation. The gel was washed in 0.9%
NaCl overnight and then stained with Coomassie Brilliant Blue
G 250.
Calculation of percent CDT and statistics
Peak areas were used for quantification of the Trf spectra. To-
tal transferrin is defined as the sum of all peak areas (isoforms
1 to 10, see Figure 4B). CDT is defined as the sum of peak ar-
eas of isoforms 7 to 10. Statistics were performed using Mi-
crosoft Excel software (Microsoft Corp., Redmont, USA).
Percent CDT measurements with TIA
Percent CDT in serum samples from alcohol consumers were
routinely analyzed using turbidimetric immunoassay (Chron
Alco I.D., Sangui BioTech, Santa Ana, USA) that measures the
sum of asialo-, monosialo-, and disialotransferrin relative to
the amount of total transferrin.
Results
The proteins from a plasma sample of a patient with
CDG-Ia were separated on two-dimensional polyacryl-
amide electrophoresis (2D PAGE) (Figure 1). The most
intense group of protein spots corresponds to serum
albumin, which accounts for more than 50% of the pro-
tein content. Using the ExPASy SWISS-2D PAGE data-
base, a series of proteins could be assigned, including
haptoglobin-1 (HPT1), α1-antitrypsin (A1AT), fibrinogen
(FIBB and FIBG), α1-β-glycoprotein (A1BG), glycine-rich
β-glycoprotein (GBG), α2-macroglobulin (A2MG), ceru-
loplasmin (CERU), and transferrin (Trf). Except for albu-
min, all above-mentioned proteins are glycoproteins,
and the best characterized of them is Trf, which is de-
tected at a molecular mass of 80 kDa and a pI of about
6.4 (Figure 1). Typically, two groups of Trf spots are ob-
served in plasma of a CDG-Ia patient, corresponding to
normal Trf (upper row) and to CDT (lower row) and rep-
resenting isoforms with different molecular masses
and pIs. The molecular mass difference reflects the in-
complete glycosylation, whereas the different pIs rep-
resent a decreasing number of sialic acid residues due
to incomplete glycosylation and various numbers of
bound Fe3 + ions. 
Figure 1 2D PAGE analysis of a plasma sample from a pa-
tient with CDG-Ia. The boxed proteins are assigned using the
ExPASy SWISS-2D PAGE database. A2MG, α2-macroglobulin;
CERU, ceruloplasmin; GBG, glycine-rich β-glycoprotein; Trf,
transferrin; A1BG, α1-β-glycoprotein; ALBU, albumin; ATAT,
α1-antitrypsin; FIBB, fibrinogen β-chain; FIBG, fibrinogen
γ-chain; HPT1, haptoglobin-1. Proteins are visualized by silver
staining.
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Figure 2 depicts a typical chromatogram of 30 µl of
plasma directly applied on the anion-exchange col-
umn. The sample was not processed before loading on
the column, and no Fe3 + saturation or pre-purification
procedures are required. Proteins were separated by
gradient elution and detected by UV absorption. The
chromatogram shows five intense and well-separated
peaks. Peaks 1 and 2 contain the salt peak (peak 1) and
other low molecular weight compounds (peak 2).
Peak 3, eluting with 20% solvent B, contains the Trf iso-
forms. Typically, fraction 3 is composed of two or three
subpeaks that were assigned to Trf isoforms with dif-
ferent numbers of bound Fe3 + ions. Saturation experi-
ments with Fe3 + ions revealed that the ratio of the sub-
peaks could be influenced by increasing the Fe3 + con-
centration (data not shown). In peak 4, we detected two
proteins with molecular masses of 51193 Da and
51863 Da (mass spectra not shown), possibly corre-
sponding to human immunoglobulin heavy chains.
The most intense peak, peak 5, contains albumin (con-
firmed by ESI-MS analysis).
In order to confirm the identity of the protein eluting
in fraction 3 (Figure 2) and to evaluate the anion-ex-
change separation, one-dimensional PAGE (1D PAGE)
Figure 2 Purification of human serum Trf by anion-exchange
HPLC and UV detection at 254 nm. Peak 3 eluting at 20% sol-
vent B contains the Trf isoforms.
Figure 3 1D PAGE analysis of the transferrin and the albu-
min fractions from anion-exchange HPLC separation. Lanes 1
and 7: low-range molecular weight marker; lane 2: 1.0 µg of to-
tal protein from a plasma sample (healthy control); lane 3:
0.1 µg of a Trf standard; lane 4: 0.1 µg of Trf fraction from a
healthy control; lane 5: 0.1 µg of Trf fraction from a CDG-Ia pa-
tient; lane 6: 0.1 µg of albumin fraction from a healthy control.
Proteins are visualized by silver staining.
Table 1 Observed and calculated molecular masses of the Trf isoforms from a patient 
with CDG-Ia (see Figure 4B). 
Isoform Molecular Molecular Assignment
(peak) mass mass
number observed calculated 
(Da) (Da)a
1 79568 79573 Most important non-CDT isoform, intact isoform containing 2 complete bi-anten-
nary N-glycans
2 79713 79720 Fucosylated isoform 1
3 79931 79940 Isoform 4 lacking a sialic acid residue
4 80227 80232 Isoform with a complete bi- and tri-antennary N-glycan; the pentasialo isoform
5 80376 80379 Fucosylated pentasialo isoform
6 79274 79281 Isoform 1 lacking a sialic acid residue
7 77358 77365 CDT isoform containing only one complete bi-antennary N-glycan
8 77507 77512 Fucosylated isoform 7
9 75152 75157 CDT isoform containing no N-glycan
10 75314 75320 Glycated isoform 9
a The assignment of the isoform structures was performed ac-
cording to the measured molecular masses. The molecular
mass of intact Trf was calculated with GPMAW (General Pro-
tein/Mass Analysis for Windows), 50% of the cysteine residues
in the protein are considered to be reduced (Cys-H), and 50% to
form disulfide bonds. Trf contains 38 Cys residues and can
form a total of 19 disulfide bonds. Addition of a complete
(bi-antennary) N-glycan moiety results in a mass shift of
+2’208 Da (12). Precision of molecular mass determination
was estimated to be about 15 Da.
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analysis was performed (Figure 3). In lane 2, 1 µg of to-
tal protein from the plasma sample was applied,
whereas in lane 3, 0.1 µg of a Trf standard was loaded.
The separated Trf fractions from a healthy control and
from a CDG-Ia patient were applied to lanes 4 and 5, re-
spectively. The albumin fraction (0.1 µg protein) was
applied to lane 6. In lanes 3, 4, and 5, all proteins had an
identical molecular mass of 80 kDa. Therefore, we con-
cluded that the protein contained in peak 3 (Figure 2)
corresponds to Trf and its isoforms. Only very faint
bands corresponding to impurities were detected in
lanes 4 and 5.
Prior to ESI-MS analysis, the Trf fraction must be
concentrated and desalted to a volume of less than
200 µl (second step of the procedure). In the third step,
the concentrated sample is subjected to reversed-
phase-HPLC (RP-HPLC) with mass spectrometric detec-
tion. Figure 4A shows a typical ESI-mass spectrum of
Trf and its isoforms obtained from a patient with CDG-
Ia. Figure 4B shows the deconvoluted mass spectrum.
All peaks of Trf are assigned according to the observed
molecular mass (Table 1). Three different groups of
mass peaks can be clearly distinguished. The group
around the peak with molecular mass 79568 Da con-
tains isoforms 1 to 6, representing isoforms with two
oligosaccharyl chains. Peak 1 (79568 Da) corresponds
to the intact isoform with two N-glycan chains contain-
ing two complete antennae each. Peak 2 (79713 Da)
shows a mass shift of +145 Da (compared with iso-
form 1) and is assigned to the fucosylated intact
isoform. Theoretically, fucosylation of a protein results
in a molecular mass increase of +147 Da. Peaks 3
Figure 4 ESI-MS analysis of Trf isolated from serum of a
CDG-Ia patient. A: ESI-mass spectrum of Trf and its isoforms.
B: Deconvoluted mass spectrum. The assignments and the
observed molecular masses of the different isoforms are
listed in Table 1. The insets show the structures of isoforms 1,
4, 7, and 9.
36
Kleinert et al.: Transferrin isoforms analyzed with ESI-MS 1585
(79931 Da), 4 (80227 Da), and 5 (80376 Da) correspond
to Trf isoforms containing N-glycan chains differing in
their degree of branching, and showing a bi- and a tri-
antennary structure. Peak 4 corresponds to the isoform
with a complete bi-antennary and a complete tri-anten-
nary N-glycan. The additional antenna consists of three
residues (N-acetylglucosamine + galactose + sialic
acid) (11) and the detected shift of +659 Da (compared
to peak 1) corresponds exactly to the calculated one.
This isoform is named a pentasialo isoform, due to the
sialic acid residues at each end of the five antennae.
Compared with the pentasialo isoform, isoform 3
shows a mass shift of –296 Da and lacks one of the five
sialic acids. The absence of one sialic acid results in a
mass shift of –292 Da, which is in good agreement with
the observed shift. Peak 5 exhibits the highest ob-
served molecular mass (80376 Da) and corresponds to
the fucosylated pentasialo isoform. An additional, low
intensity peak is detected at 79274 Da (isoform 6), prob-
ably representing the non-CDT isoform lacking one of
the four sialic acids.
The groups around the peaks at 77358 Da (isoform 7)
and 75152 Da (isoform 9) correspond to carbohydrate-
deficient Trf isoforms and both contain two peaks. Iso-
form 7 is assigned to a CDT isoform with only one of
the two bi-antennary N-glycans, and peak 8 (77507 Da)
is assigned to its fucosylated species. Isoform 9 is com-
pletely deglycosylated, and a low intensity peak at
75314 Da (isoform 10) is observed. Isoforms 9 and 10
show a mass difference of 162 Da. Therefore, we con-
cluded that isoform 10 is probably a glycated species of
isoform 9. Conjugation with a hexose (e.g., glucose,
galactose, mannose) would lead to a mass shift of
+163 Da, which corresponds well with the observed
mass difference. 
Figure 5 shows the Trf pattern of a control and three
patients. In the spectrum of a healthy control, the intact
Trf is the most abundant isoform (Figure 5A). Only a
faint peak corresponding to the CDT isoform 7 is de-
tected. Figure 5B shows the Trf pattern of a CDG-Ia pa-
tient. All other CDG-I subtypes revealed similar pat-
terns differing only in the intensities of the peaks. As
outlined above, up to 10 different isoforms containing
two, one, or no oligosaccharyl chains (complete or in-
complete) are observed in the spectrum. The Trf mass
spectrum of a CDG-IIa patient (Figure 5C) is completely
different when compared to that of a CDG-Ia patient.
The base peak at 78246 Da corresponds to an isoform
containing two incompletely glycosylated oligosaccha-
rides. In both N-glycans, the lack of N-acetylglu-
cosaminyl transferase II, which is characteristic for
CDG-IIa, results in a deficiency of the antennary arm
connected through the Man (α13) linkage (18). Trun-
cation of the N-glycans results in a theoretical mass
shift of –1318 Da and corresponds well with the ob-
served shift of –1322 Da. Finally, the Trf pattern of an al-
cohol abuser (Figure 5D) looks similar to that of the
healthy control, but CDT isoform 7 is clearly elevated.
Figure 5 ESI-mass spectra of Trf isolated from plasma/serum of different patients. 
A: healthy control; B: CDG-Ia patient; C: CDG-IIa patient; D: alcohol abuser.
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We analyzed plasma samples from 20 healthy con-
trols as well as nine samples from patients with CDG-Ia,
and one sample each of CDG-Ib, CDG-Ic, CDG-Ie, CDG-
If, and CDG-IIa patients. Furthermore, samples from 20
patients with cystic fibrosis were analyzed. The results
are summarized in Table 2. We found a normal value for
CDT of 1.6% (of total Trf) with a coefficient of variation
(CV) of 39% in healthy controls, where the upper limit of
the 95% confidence interval was 2.9%. In patients with
cystic fibrosis, the mean value was slightly elevated
(1.8%), however, there was no statistically significant
difference between the two groups. On the other hand,
all samples from CDG-Ia patients exhibited clearly in-
creased CDT values, ranging from 21.0% up to 51.2%.
Equally, all samples from patients with other CDG types
(CDG-I and CDG-II) showed evidently elevated levels 
of CDT ranging from 22.2% (CDG-Ib) up to 100% in
CDG-IIa. Serum samples of CDG-Ia, CDG-Ib, CDG-Ic,
CDG-Ie, CDG-If, and CDG-IIa patients, of an alcohol
abuser, and of a healthy control were also analyzed by
IEF (Figure 6). All pathological samples showed clearly
elevated levels of CDT (two sialic acids).
Additionally, 27 sera that were found with TIA to con-
tain elevated levels of CDT (>2.5%) were analyzed.
With our method, 11 out of 27 samples showed in-
creased CDT values (>2.9%). However, all the samples
containing CDT levels higher than 4.5% (when ana-
lyzed with TIA) also showed increased levels when an-
alyzed with mass spectrometry. 
Finally, two CSF samples from children were ana-
lyzed. In CSF, the total protein concentration is about
100 times lower than in plasma or serum, therefore we
used 4 ml of CSF for the Trf analysis. After concentra-
tion to a volume lower than 200 µl, the samples were
processed according to the three-step procedure. The
Trf pattern of CSF is similar to that of healthy control
plasma and shows no additional isoforms (Figure 7).
Discussion
Analysis of human serum Trf plays an important role
for the diagnosis of CDG (19, 20) and allows differenti-
ation between CDG-I and CDG-II subtypes. Further-
more, CDT is a marker of alcohol abuse (6). CDT is also
elevated in chronic obstructive pulmonary disease
(COPD) (21) and cystic fibrosis (22), and in many other
disorders (6, 7). The analysis of Trf isoforms demands
highly sensitive and specific techniques. Whereas
most of the common procedures are based on elec-
trophoretic or chromatographic methods (23, 24), we
identified the isoforms according to their molecular
Table 2 Determined CDT levels in healthy controls, in patients with cystic fibrosis, 
and those with CDG. 
Patients Number of Mean CDT Median CDT Standard Coefficient 
samples (% of total (% of total deviation of variation 
transferrin) transferrin) (%)
Healthy controls 20 1.6 1.6 0.6 39
Cystic fibrosis 20 1.8 1.7 0.8 44
CDG-Ia 9 37.4 40.0 10.0 27
CDG-Ib 1 22.2a
CDG-Ic 1 56.1a
CDG-Ie 1 25.2a
CDG-If 1 25.0a
CDG-IIa 1 (100.0)b
a Single value; b characterized by loss of an antenna in both N-glycans.
Figure 6 IEF of serum samples of a healthy control (lanes 1
and 9) and of patients with CDG-Ia (lane 2), CDG-Ib (lane 3),
CDG-Ic (lane 4), CDG-Ie (lane 5), CDG-If (lane 6), CDG-IIa (lane
7), and of an alcohol abuser (lane 8).
Figure 7 ESI-mass spectrum of Trf isolated from 4 ml human
CSF.
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masses, a method that allows an unambiguous deter-
mination of the Trf isoforms in different human body
fluids. With our method, no Fe3 + saturation is neces-
sary, and anticoagulants such as heparin, EDTA, citrate,
and oxalate (8) do not interfere with the analysis.
The Trf pattern of a CDG-Ia patient showed a series of
10 different isoforms (Figure 4B). The intact isoform
(peak 1), usually the base peak, contains two covalently
linked N-glycans, whereas peaks 7 and 9 correspond to
the classical forms lacking one and both bi-antennary
glycans, respectively. All other isoforms are due to sev-
eral modifications of the main isoforms 1, 7, and 9.
Peaks 2, 5, and 8 represent fucosylated forms. Besides
fucosylation, different types of substitution that can oc-
cur on the core of complex-type N-glycans are xylosy-
lation, or N-acetyl-D-galactosaminylation (25). Fucosy-
lation can occur on the two N-acetyl-D-glucosamine
residues of the core. Trf isolated from a human hepato-
carcinoma cell line has been shown to contain large
amounts of higher antennary oligosaccharides with
proximal, as well as peripheral, fucose (26). Whether
one of the two N-glycans in Trf is preferred for fucosy-
lation is not known. The fucosylation of glycoproteins
was found to be deficient in patients with a clinical phe-
notype resembling that of patients with leukocyte-ad-
hesion deficiency type II (27).
Isoform 4 contains a bi- and a tri-antennary oligosac-
charyl chain. In addition to the bi-antennary glycan
structure, the tri-antennary structure belongs to the
most common N-glycan chains of Trf (18). Isoform 4
and the fucosylated isoform 5 belong to pentasialo Trf
(11). 
In all samples, isoforms 3 and 6, which lack one sialic
acid residue, showed very weak signals, or occasion-
ally they were completely absent. In contrast to the
work of Bergen et al. (11), we were able to detect these
isoforms, but we agree that the Trf glycoforms detected
in CDG-I and chronic alcoholic patients reflect the ab-
sence of entire glycan side chains and not of individual
sialic acids. Isoform 10 probably corresponds to a gly-
cated species. The non-enzymatic reaction of carbohy-
drates with primary amine groups of the protein (e.g.,
the N-terminal amino group) forms a Schiff base,
which then rearranges into a stable adduct (18). Exam-
ples for glycated plasma proteins are hemoglobin
β-chain in HbA1c and glycated albumin.
The method was tested by analyzing plasma and
serum from controls, from patients with cystic fibrosis,
with CDG-Ia, CDG-Ib, CDG-Ic, CDG-Ie, CDG-If, and CDG-
IIa, as well as from excessive alcohol consumers
(Table 2). As a result of different analytical specificities
and recoveries, reference range values for absolute and
relative CDT are method-dependent (6, 24). Our method
revealed a CDT mean value of 1.6% (% of total Trf) for
healthy controls. Larsson et al. (22) reported increased
serum concentrations of CDT in patients with cystic fi-
brosis in 1998. They reported a slightly increased CDT
mean of 0.954% (healthy controls: 0.735%), but unfortu-
nately no standard deviation was given. The absence of
a statistical evaluation of the data means that the signif-
icance of the difference in the two given values cannot
be determined and an interpretation of the data is se-
verely limited. However, we found no statistically sig-
nificant difference between the mean values of healthy
controls and of cystic fibrosis patients. 
Furthermore, we analyzed several samples that were
found with TIA to have elevated CDT values. Unfortu-
nately, for ethical reasons, we have no information
about the severity of the alcoholism of these patients.
Therefore, we intend to perform further investigations
with samples from accurately documented alcohol
abusers in order to evaluate further the suitability of
our method in the field of alcohol abuse detection. 
All samples from patients with CDG-I disorders con-
tained highly elevated CDT levels, ranging from 21.0%
in CDG-Ia up to 56.1% in CDG-Ic. All samples showed
similar Trf patterns, therefore, it is not possible to deter-
mine the subtype of the CDG-I disorder with mass spec-
trometric means. In contrast to the CDG-I pattern, the
Trf pattern of the CDT-IIa sample (Figure 5C) is very
characteristic and exhibits only one prominent isoform.
CDG-I disorders are caused by defects of enzymes in-
volved in N-glycan assembly, whereas CDG-II disorders
are caused by defects in the N-glycan processing.
N-glycan assembly is carried out in endoplasmic reticu-
lum (ER) and results in a lipid-linked oligosaccharide.
The oligosaccharide moiety is then transferred to se-
lected asparagines in the nascent protein. Finally, the
newly formed glycoprotein is processed in the ER and
the Golgi by trimming off the three glucoses and six
mannoses and replacing these with two residues each
of N-acetylglucosamine, galactose, and sialic acid (19). 
Serum samples of the CDG patients studied by ESI-
MS were also analyzed by IEF (Figure 6). The relative
distribution between the tetrasialo and disialo bands
visible on the IEF gel correlated well with the CDT val-
ues listed in Table 2.
Besides serum and plasma samples, we analyzed
two CSF samples (see Figure 7). The acquired Trf spec-
tra of the CSF samples were similar to those in serum.
Surprisingly, we found no “brain-type” glycosylated
isoforms as postulated in (26). Maybe this result is due
to the fact that we analyzed CSF from children. Further
investigations of Trf in CSF of healthy controls and of
CDG patients have to be performed in order to obtain a
more detailed insight into the Trf pathway in brain and
in possible brain-type glycosylation.
In conclusion, our results show that the method pre-
sented here is well suited for the analysis of Trf and its
isoforms. It is applicable to several types of samples
(serum, plasma, CSF) and may also be applied to
plasma samples spotted on Guthrie cards. The method
is a useful tool for the detection of disorders that are as-
sociated with increased levels of CDT, as well as for
monitoring therapies.
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Effect of glycosylation on the protein pattern
in 2-D-gel electrophoresis
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Single proteins, when analyzed with 2-D-PAGE, often show multiple spots due to PTMs. In gels
of human body fluids, the spot patterns facilitate the assignment and identification of the pro-
teins. We analyzed serums from patients with congenital disorders of glycosylation (CDG) in
which glycoproteins are strongly impacted and exhibit highly distinguishable spot patterns
compared to healthy controls. We detected a typical protein pattern for a1-acid glycoprotein
(AGP) and transferrin (Trf) that are markers for CDG. AGP contains five glycosylation sites
which results in a complex microheterogeneity of the glycoprotein. On the other hand, in Trf, a
glycoprotein with only two glycosylation sites, mainly biantennary complex-type-N-linked gly-
cans are bound. We used 2-D-PAGE, MALDI-TOF-MS, and ESI-MS for the analysis of these
glycoproteins and their corresponding glycans. In AGP, the heterogenic glycosylation of the dif-
ferent glycosylation sites is responsible for the complex spot pattern. In contrast to AGP, the
protein spots of Trf cannot be explained by glycosylation. We found strong evidence that oxida-
tion of cysteine is responsible for the spot pattern. This study contradicts the commonly accepted
assumption that the multiple protein spots of Trf observed in 2-D-PAGE are due, as in AGP, to
the glycosylation of the protein.
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1 Introduction
2-D-PAGE is still the most powerful method for the analysis of
crude protein mixtures. The major drawbacks of this method
are the limited sensitivity, the inconvenience of the analysis for
membrane proteins, and its application is rather time-con-
suming. Nevertheless, this method allows the analysis of sev-
eral hundred proteins in a single experiment. In addition, the
method is selective, specific, reproducible, and reliable.
Examining 2-D-gels of body fluids, a microheterogeneity
of proteins is often observed due to PTMs of the proteins,
such as glycosylation and phosphorylation. Glycosylation
plays a central role among the PTMs of human proteins, and
the majority of plasma proteins are glycoconjugates in which
one or more glycans are covalently linked to amino acid side
chains [1]. In O-linked glycosylated proteins, the carbohy-
drates are linked to serine or threonine side chains, whereas
in N-linked glycoproteins the glycans are bound to aspar-
agine side chains. N-glycosylation is important for proper
folding of newly synthesized polypeptides [2]. Proteins are
N-glycosylated by a complex series of enzymatic reactions [3].
Congenital disorders of glycosylation (CDG) are genetic dis-
orders resulting from abnormal glycosylation of glycoconju-
gates [3–5]. CDG are classified as type I or II based on the
position of the defect in the glycosylation pathway. The CDG-
I group are N-glycan assembly disorders that become mani-
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fested in proteins by the lack of complete glycans. Currently,
12 defects termed CDG-I (a-l) are known [6]. CDG-Ia is by far
the most common and best-studied CDG with an estimate of
700 cases worldwide. The CDG-II group comprises six
defects of the processing pathway of N-glycosylation which
are named CDG-IIa- to CDG-IIf. Patients with these defects
exhibit plasma proteins that are fully glycosylated but the
glycans are truncated [1].
In the studies of Mills et al. [7, 8], 2-D-PAGE was applied
for the analysis of variants and glycoisoforms of a1-anti-
trypsin in plasma samples of a patient with CDG-Ia and from
patients with specific alterations in the structure of this pro-
tein. Additionally, they analyzed the glycans in the different
a1-antitrypsin spots and attributed the multiple forms of a1-
antitrypsin to different numbers of sialic acid residues on the
glycans and to truncated isoforms that are formed by the loss
of five N-terminal amino acids [7].
In this study, we investigated the protein spot patterns of
a1-acid glycoprotein (AGP), a glycoprotein with a very com-
plex glycosylation, and of transferrin (Trf), a protein with
homogeneous glycosylation. AGP and Trf are abundant in
plasma but they differ significantly in their carbohydrate
content. Whereas in AGP, the glycan content is very high
with amounts up to 45%, in Trf (Swiss-Prot No. P02787) it is
only 6% of the molecular mass. AGP is a 41–43 kDa acute
phase protein with very low pI and consists of a major com-
ponent (P02763, orosomucoid-1) and a minor component
(P19652, orosomucoid-2). It is synthesized in the liver and its
production is increased following the response to various
stressful stimuli [9]. AGP has five glycosylation sites that
carry tetraantennary as well as di- and triantennary glycans.
On the other hand, the iron-transport glycoprotein Trf con-
sists of a single polypeptide chain with only two oligo-
saccharide binding sites that are mainly occupied by dian-
tennary glycans [10]. Trf is an 80 kDa protein which can bind
two Fe31 ions and is expressed mainly in the liver.
We compared the protein patterns of AGP and Trf in
serum samples from healthy controls and from patients with
CDG-Ia and CDG-IIa. Furthermore, the glycans cleaved from
the proteins isolated from different spots were investigated
with MALDI-TOF-MS, and the glycan profiles were used for
the interpretation of the spot patterns.
2 Materials and methods
2.1 2-D-SDS-PAGE
2.1.1 Narrow-range IEF (analysis of AGP)
Sample preparation, IEF, and equilibration of the strips were
performed according to the method of Bjellqvist et al. [11]. A
volume of 1.2 mL serum for analytical and 20 mL for pre-
parative gels (for glycan analysis) were loaded and focused
on Immobiline DryStrips (Amersham Biosciences,
Uppsala, Sweden, 18 cm, pH 3.5–4.5) using an IPGphor
electrophoresis unit (Amersham Pharmacia Biotech). After
equilibration, 2 cm of the strip was removed from the ca-
thodic end prior to the separation in the second dimension.
2.1.2 Wide-range IEF (analysis of Trf)
Before 2-D-gel analysis, Trf was isolated from serum samples
as described in [10]. Sample volumes of 6 and 50 mL of serum
were applied for analytical and preparative gels, respectively.
IEF was performed according to standard protocols [12]
using IPG strips with a pH gradient of 5–8 (BioRad, Her-
cules, CA, ReadyStrip, 17 cm). Samples were applied by in-
gel rehydration. After equilibration, 1 cm of the strip was
removed from the anodic end prior to the separation in the
second dimension.
2.1.3 2-DE
SDS-PAGE was carried out on a Protean II xi system
(BioRad). Gels consisted of 10% (narrow-range gels) or 8%
(wide-range gels) w/v acrylamide with 2.7% piperazine dia-
crylamide (PDA) as crosslinker. Gel dimensions were
20 cm616 cm60.15 cm and running conditions were
40 mA/gel at 157C. Proteins on analytical gels were visual-
ized by a long silver nitrate staining, whereas preparative gels
were stained with colloidal Coomassie Brilliant Blue G as
described in [13].
2.2 Deglycosylation
2.2.1 In-gel deglycosylation
Protein spots were excised from the gels and cut into small
pieces, washed with H2O, destained with several changes of
washing solution (50% ACN in 2 mM Tris, pH = 7), and
shrunk in ACN for 10 min. The gel pieces were dried and
then soaked in a 2 mM Tris (pH = 7) solution containing
0.1 U/mL N-glycosidase F (Roche Diagnostics, Mannheim,
Germany). Excess enzyme solution was removed and the gel
pieces were covered with 2 mM Tris (pH = 7). Deglycosyla-
tion was performed at 377C overnight. Glycans were extract-
ed using three changes of 200 mL of H2O with sonication for
30 min. All extracts were combined and concentrated to ap-
proximately 5–10 mL (SpeedVac centrifuge). The samples
were desalted with 0.6 mL of cation exchange resin (AG50W-
X8 resin, hydrogen form, 100–200 mesh) packed into a
micro-spin chromatography column (BioRad).
2.2.2 In vitro deglycosylation of Trf
Trf (50 mg; Sigma-Aldrich St. Louis, MO) was incubated at
957C in 10 mL of a 0.1% SDS solution for 5 min. The dena-
tured sample was diluted to 100 mL with a solution contain-
ing 0.1 U/mL N-glycosidase F and incubated overnight at
377C. Ten microliters of the degylcosylated solution was used
for ESI-MS analysis and 2 mL for 2-D-SDS-PAGE analysis.
 2007 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.proteomics-journal.com
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2.3 MALDI-TOF-MS analysis of glycans
MS analysis was carried out on an autoflex MALDI-TOF
instrument fitted with a 337 nm UV laser (Bruker Daltonics,
Leipzig, Germany). Glycans were analyzed in the linear
negative-ion mode with delayed extraction (60 ns). The fol-
lowing voltages were applied: source 20 kV; extraction
18.4 kV; and lens 7.9 kV. Analyte solution (0.5 mL) was applied
on a 400-mm AnchorChip target (Bruker Daltonics). After
drying, 0.5 mL of trihydroxyacetophenone/ammonium citrate
matrix was added and immediately dried under vacuum [14].
The sample was then allowed to absorb moisture from the
atmosphere to promote the formation of small crystals.
2.4 Isolation and ESI-MS analysis of Trf
Trf was isolated from plasma or serum samples and analyzed
using ESI-MS according to the methods described in [10].
2.5 Enzymatic digestion of Trf and
LC-MALDI-TOF-MS analysis of the peptides
Trf (10 mg) was incubated in 10 mL of a solution containing
150 mM Tris, 6 M urea, and 6 mM EDTA (pH = 8) for 2 h at
377C. Five microliters of a solution containing 0.5 mg of
endoproteinase Lys C (Roche Diagnostics) and 45 mL of H2O
were added and incubated overnight at 377C. The digest
(6 mL) was loaded on a RP capillary HPLC column (PepMap
C18, 0.3 mm6150 mm, LC Packings, Amsterdam, Nether-
lands). Peptides were separated with the following HPLC
program: (i) isocratic flow 5% solvent B v/v for 5 min; (ii)
linear gradient from 5 to 20% B in 5 min; (iii) linear gradient
from 20 to 60% B in 20 min; (iv) linear gradient from 60 to
100% B in 5 min; and (v) isocratic flow of 100% B for 10 min.
Solvents A and B were 0.1 and 0.07% TFA in 80% ACN,
respectively. The flow rate was 4 mL/min. Peptides were col-
lected onto a prespotted (CHCA) AnchorChipTM target (Bru-
ker Daltonics) using a Probot microfraction collector (LC
Packings), and fractions were collected in 20 s intervals.
Mass mapping was performed with an autoflex MALDI-
TOF-MS. Peptides were analyzed in the positive ion mode
with delayed extraction (70 ns), and the following voltages
were applied: source 19 kV; extraction 16.55 kV; lens 8.35 kV;
and reflector 20 kV.
3 Results and discussion
3.1 Analysis of AGP protein spot pattern
Due to the low pI of AGP, we performed narrow-range 2-D-
PAGE with IEF strips ranging from pI 3.5 to 4.5 without any
prefractionation of the plasma samples. Figure 1 presents
the silver-stained, narrow-range 2-D-gels of a control sample
(Fig. 1A), a CDG-Ia (Fig. 1B), and a CDG-IIa (Fig. 1C)
patient.
Figure 1. Narrow-range 2-D-gels of AGP from a control plasma
sample (A), a patient with CDG-Ia (B), and a CDG-IIa (C). Proteins
are visualized using a silver-staining procedure.
The AGP protein spots in Fig. 1A appear as a descending
row of well-separated spots with increasing pI and decreas-
ing molecular mass corresponding to differently glycated
AGP isoforms. The more acidic AGP isoforms (pI,3.75)
contain glycans with higher content of SAs (sialic acids) and
with slightly increased molecular masses, e.g., glycans with
tri- and tetraantennary N-linked oligosaccharides. The more
basic isoforms (pI.3.75) exhibit lower molecular masses
and a lower content of SAs due to higher amounts of bian-
tennary glycans. A single AGP-spot consists of several iso-
forms that have the same number of SAs but different glycan
distributions in the five glycosylation sites. The oval shape of
these spots is explained by the different molecular masses of
the isoforms.
There are two overlapping rows of spots attributed to the
two naturally occuring variants, orosomucoid-1 (major var-
iant of AGP) and orosomucoid-2 (minor variant), encoded by
two different genes. The variants differ in 22 amino acids
whereas the molecular mass difference is 91 Da and the pI
difference is 0.12 U.
Figure 1B presents the narrow-range 2-D-gel of AGP
from a patient with CDG-Ia. This disorder is characterized by
an incomplete glycosylation of proteins. Compared to the
control sample (Fig. 1A), in Fig. 1B, two additional rows of
spots containing uncompletely glycosylated isoforms are
visible. Whereas the upper row of spots represents the five-
fold (completely) glycosylated AGP isoforms, the lower rows
contain four- and three-fold glycosylated isoforms, respec-
tively. The hypoglycosylated isoforms exhibit lower molecu-
lar masses and a shift to more basic pIs as a result of a lower
number of SAs.
An entirely different spot pattern is found in the narrow-
range 2-D-gel of AGP from a patient with CDG-IIa (Fig. 1C).
In this disorder, patients lack N-acetylglucosaminyl transfer-
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ase II acitivity and, therefore, N-acetylglucosamine residues
cannot be attached in the a1? 6 position of the core, resulting
in incomplete structures [1]. All di-, tri-, and tetraantennary
glycans are missing at least one antenna. This results in a
clear shift to more basic pIs. Furthermore, fewer isoforms
with different glycosylation but identical pI are possible;
therefore, the spots are less diffuse.
3.2 Analysis of AGP-glycans with MALDI-TOF-MS
In order to confirm the results given in the previous section,
we digested the AGP-spots with N-glycosidase F and ana-
lyzed the isolated glycans with MALDI-TOF-MS. Figure 2
shows the mass spectra of the glycans isolated from an acidic
(the inset of Fig. 2A shows the selected spot at pI = 3.6) and a
basic spot (Fig. 2B, spot at pI = 3.85). In the upper spectrum,
the relative amount of glycans (including fucosylated spe-
cies) was 11% (diantennary), 53% (triantennary), and 36%
(tetraantennary), calculated by adding the peak areas. The
corresponding amounts in the basic spot were 30, 52, and
18%. These results clearly show a prominent shift from tet-
raantennary glycans in the acidic spot to diantennary glycans
in the basic spot. Similiar results were also found for the
AGP-spots excised from the lower rows in the CDG-Ia sam-
ple (data not shown). Assignment of the peaks was per-
formed according to the observed molecular masses and is
summarized in Table 1. During MALDI analysis, glycans are
likely to loose terminal SAs [15]. Therefore, glycans missing
one or several SAs are mainly artefacts from the MALDI
measurement.
From the 2-D-PAGE analyses and the mass spectromet-
ric glycan analyses, we conclude that, for AGP, the protein
spot pattern is mainly due to different glycosylation and to
the different variants, orosomucoid-1 and orosomucoid-2.
3.3 Analysis of Trf protein spot pattern
Figure 3 illustrates the 2-D-gels of Trf, the most important
protein marker for CDG, isolated from plasma samples of a
control (Fig. 3A), a CDG-Ia (Fig. 3B), and a CDG-IIa patient
(Fig. 3C). The control sample (Fig. 3A) exhibits a pattern with
three major spots with pIs ranging from 6.1 to 6.3 and sev-
eral minor spots. The CDG-Ia sample (Fig. 3B) exhibits an
additional row of spots corresponding to Trf molecules
missing one of the two complete glycans. Furthermore, a row
of faint spots with lower molecular mass is observed corre-
sponding to Trf without any bound oligosaccharide. These
carbohydrate-deficient transferrin (CDT) spots all show a
Figure 2. MALDI-TOF-mass
spectra (negative ion mode) of
glycans isolated from an acidic
AGP-spot (A; pI = 3.6) and a
basic AGP-spot (B; pI = 3.85).
The insets show the Coomassie-
stained preparative gels, and the
spots marked with arrows were
used for glycan analysis.
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Table 1. Symbols, structures, and molecular masses of enzyma-
tically released glycans from AGP and Trf
Symbol Glycan Molecular
mass
(M 2 H)2
Diantennary glycan missing 1 SA 1931.8
Diantennary glycan 2223.0
Triantennary glycan missing 2 SA 2297.1
Fucosylated triantennary glycan
missing 2 SA
2443.3
Triantennary glycan missing 1 SA 2588.4
Tetraantennary glycan missing 3 SA 2662.4
Fucosylated triantennary glycan
missing 1 SA
2734.5
Fucosylated tetraantennary glycan
missing 3 SA
2808.6
Triantennary glycan 2879.6
Tetraantennary glycan missing 2 SA 2953.7
Fucosylated triantennary glycan 3025.8
Fucosylated tetraantennary glycan
missing 2 SA
3099.9
Tetraantennary glycan missing 1 SA 3244.9
Fucosylated tetraantennary glycan
missing 1 SA
3391.1
Tetraantennary glycan 3536.2
Fucosylated tetraantennary glycan 3682.4
SA: sialic acid(s).
distinct shift to more basic pIs due to lower amounts of SA
residues and exhibit a clearly detectable mass shift of 2.2 kDa
(missing one glycan) and 4.4 kDa (missing both glycans).
Our results correspond well with the patterns of a control
and a CDG-I patient as published in [16]. The 2-D-gel of the
CDG-IIa sample (Fig. 3C) exhibits a similar protein spot
Figure 3. 2-D-gels of transferrins from a control plasma sample
(A), a patient with CDG-Ia (B) and CDG-IIa (C). Proteins are visu-
alized using a silver-staining procedure.
pattern as found in the second row of spots in Fig. 3B. This
finding corresponds well with the number of SAs bound to
the CDT isoforms in CDG-Ia and CDG-IIa. These isoforms
contain only two SA residues.
3.4 Analysis of Trf-glycans with MALDI-TOF-MS
In a previous study [10], we analyzed Trf with ESI-MS and
found that it consists mainly of the tetrasialoisoform (iso-
form at mass 79 568 Da containing four SA residues). Other
isoforms were detected only in small amounts. Therefore, in
2-D-PAGE we would expect only one prominent spot that
corresponds to the tetrasialo isoform of Trf and several far
less intense spots corresponding to the minor isoforms. We
had no explanation for the three major spots observed in
Fig. 3A. Investigation of the glycans from an acidic and a
basic Trf spot revealed very similar mass spectra (Fig. 4) with
only two intense oligosaccharides, the diantennary glycan
and its corresponding glycan missing one SA. ESI-MS anal-
ysis of Trf revealed low amounts of Trf isoforms missing an
SA [10]. Therefore, the glycan missing an SA is due to tech-
nical artefacts produced by the MALDI process. From these
results, we conclude that the protein spot pattern observed in
Trf samples is not due to different carbohydrate composi-
tions of the glycans, but must have another origin.
3.5 Protein spot pattern of deglycosylated Trf
In order to confirm this assumption, we enzymatically
cleaved the glycans from Trf and analyzed the protein with
ESI-MS and 2-D-SDS-PAGE. Figure 5 illustrates the decon-
voluted ESI-mass spectra of native (Fig. 5A) and deglyco-
sylated (Fig. 5B) Trf and its corresponding 2-D-gels (insets).
The peaks at 79 568 and 75 152 Da correspond to completely
glycosylated and deglycosylated Trf, respectively. Both sam-
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Figure 4. MALDI-TOF-mass
spectra (negative ion mode) of
glycans isolated from an acidic
(A; pI = 6.2) and a basic Trf-spot
(B; pI = 6.4). The insets show the
Coomassie-stained preparative
gels, and the spots marked with
arrows were used for glycan
analysis.
ples showed similar spot patterns that differ in a pI shift in
the deglycosylated sample due to the loss of four SAs and in a
shift to lower molecular mass. We concluded that the Trf spot
pattern is not due to the protein glycosylation but must arise
from the protein core.
3.6 Cysteine oxidation in Trf
As a result of the strongly denaturing conditions applied in
2-D-PAGE, Fe31-, and bicarbonate binding of Trf could not be
responsible for the spot pattern. No intense mass peaks cor-
responding to post-translationally modified or truncated Trf
were found in the ESI-mass spectrum (Fig. 5A). We were
able to separate peaks with mass shifts larger than about
40 Da. Therefore, only PTMs leading to a mass shift of less
than 40 Da could be responsible for the pI change of Trf
observed in 2-D-PAGE. Oxidation is a frequently observed
modification that results in a mass shift of 16 Da (per oxida-
tion), and, if cysteine residues are oxidized, leads to a pI
change due to the conversion into sulfenic acid (Cys-SOH),
sulfinic acid (Cys-SO2H), or sulfonic acid (Cys-SO3H).
Methionine is the best known subject of oxidation [17], how-
ever, this modification does not result in a significant charge
change. Cysteine oxidation was observed under oxidative
stress conditions [18, 19], but was also reported under physi-
ological conditions without an exogeneous oxidant [20]. Pro-
teins with oxidized cysteine residues are separated in 2-D-
PAGE due to the addition of a single negative charge to the
protein [18, 19, 21].
In order to identify oxidized cysteine residues in Trf, we
analyzed an endoproteinase Lys-C digest of Trf with LC-
MALDI-TOF-MS and scanned for peptide masses that show
mass shifts of 116, 132, or 148 Da (one- to three-fold oxi-
dation). Several of the methionine-containing peptides
exhibited the expected mass shifts, however, methionine is
easily oxidized to sulfoxide in the solution and in the solid
state, and this process can be accelerated when exposed to
UV- or daylight [22]. Therefore, candidate peptides should
contain at least one of the 38 cysteines and no methionine.
We found a peptide with mass 2143.9 Da that was assigned
to peptide aa(471–489) of Trf (Fig. 6) and confirmed the
assignment by PSD (data not shown). It contains two cyste-
ine residues but no methionine. An additional peptide
appears at 2141.9 Da and corresponds to the peptide with an
intramolecular disulfide bond. Both peptides showed oxi-
dized species at 2175.9 and 2173.9 Da. The mass shift of
32 Da suggests a two-fold oxidation of one of the cysteine
residue to the corresponding sulfinic acid rather than the
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Figure 5. ESI-mass spectra of Trf (A) and deglycosylated Trf (B).
The insets show the silver-stained 2-D-gels of the corresponding
Trf samples that exhibit similar protein spot patterns. A distinct
shift to more basic pIs is observed in the deglycosylated sample.
generation of two sulfenic acids. The sulfenic acid group is
usually unstable [23–25] and either reacts with any accessible
thiol to form a disulfide or undergoes further oxidation to
sulfinic acid [26]. Possibly, sulfinic acid can also react with
thiol to form a disulfide, explaining the oxidized peptide with
the intramolecular disulfide bond observed at 2173.9 Da.
PSD analysis of the oxidized species was not successful be-
cause of limited signal intensity. However, we observed pep-
tides at masses 2271.9 and 2269.9 Da that are assigned to the
same peptides with one missed cleavage (aa(471–490)). Their
corresponding oxidized species at 2303.9 and 2301.9 Da were
also detected (data not shown).
It still remains to be elucidated whether cysteine oxida-
tion is due to artifacts of the analysis procedures (2-D-PAGE,
digestion, MALDI-TOF-MS) or occurs in nature.
4 Concluding remarks
Analysis and interpretation of protein spot patterns in 2-D-
PAGE reveals important information about PTMs of pro-
teins. In diseases that alter the PTM of proteins, such as
CDG (types I and II), the protein patterns can be used as re-
liable markers. However, to explain the origin of the patterns
of glycoproteins, careful analysis of the proteins and the
Figure 6. MALDI-TOF-mass spectrum of a tryptic peptide of Trf
exhibiting two-fold oxidation of cysteine residues. The masses
2143.9 and 2141.9 Da are assigned to aa(471–489) with the
sequence INHCRFDEFFSEGCAPGSK and to the peptide with an
intramolecular disulfide bond, respectively. The masses 2175.9
and 2173.9 Da are assigned to the corresponding oxidized spe-
cies.
bound glycans is essential. As shown in this study, glycosy-
lation is mainly responsible for the complex pattern in AGP,
but protein variants also contribute to the complexity. In
contrast, the very homogeneous glycosylation in Trf has no
influence on the pattern in samples from healthy controls,
and we disproved the commonly accepted assumption that
the Trf spot pattern observed in 2-D-PAGE is due to glycosy-
lation. We found strong evidence that oxidation of cysteine
residues to sulfinic acid (RSO2H) is responsible for the
charge change of Trf molecules. In this study, we demon-
strated that the obvious conclusion, that a spot pattern of a
glycoprotein in 2-D-PAGE must be due to its glycosylation,
could be wrong and misleading.
We are grateful to Dr. Rowena Crockett for critical reading of
the manuscript. We thank Dr. Bernd Roschitzki for special mass
spectrometric analyses.
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Hepatic Carnitine Palmitoyltransferase I
Deficiency: Acylcarnitine Profiles in Blood Spots
Are Highly Specific
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Background: In carnitine palmitoyltransferase I (CPT-I)
deficiency (MIM 255120), free carnitine can be increased
with no pathologic acylcarnitine species detectable. As
inclusion of CPT-I deficiency in high-risk and newborn
screening could prevent potentially life-threatening
complications, we tested whether CPT-I deficiency
might be diagnosed by electrospray ionization-tandem
mass spectrometry (ESI-MS/MS).
Methods: A 3.2-mm spot of whole blood dried on filter
paper was extracted with 150 mL of methanol. After
derivatization of carnitine and acylcarnitines to their
butyl esters, the samples were analyzed by ESI-MS/MS
with 37.5 pmol of L-[2H3]carnitine and 7.5 pmol of
L-[2H3]palmitoylcarnitine as internal standards.
Results: In all dried-blood specimens from each of three
patients with CPT-I deficiency, we found an invariably
increased ratio of free carnitine to the sum of palmitoyl-
carnitine and stearoylcarnitine [C0/(C16 1 C18)]. The
ratio in patients was between 175 and 2000, or 5- to
60-fold higher than the ratio for the 99.9th centile of the
normal newborn population in Bavaria (n 5 177 842).
No overlap with the values of children that were known
to be supplemented with carnitine was detected [C0/
(C16 1 C18), 34 6 30; mean 6 SD; n 5 27].
Conclusions: ESI-MS/MS provides a highly specific
acylcarnitine profile from dried-blood samples. The
ratio of free carnitine to the sum of palmitoylcarnitine
and stearoylcarnitine [C0/(C16 1 C18)] is highly specific
for CPT-I deficiency and may allow presymptomatic
diagnosis.
© 2001 American Association for Clinical Chemistry
In carnitine palmitoyltransferase I (CPT-I)5 deficiency
(MIM 255120), long-chain fatty acids are not transferred
from CoA to carnitine to form acylcarnitines by palmitoyl-
CoA:l-carnitine O-palmitoyltransferase (EC 2.3.1.21).
Thus, they cannot enter the mitochondria for subsequent
b-oxidation (1 ). There are two distinct tissue-specific
isoforms of the enzyme: the liver-type isoform (CPT-IA)
and the muscle-type isoform (CPT-IB) (2, 3). The two
isoforms are encoded by two different genes (4 ). Whereas
CPT-IA is expressed in liver, kidney, and fibroblasts and
CPT-IB is expressed in skeletal muscle, cardiac ventricular
myocytes are the only cells known to express both iso-
forms. CPT-IA and CPT-IB are subject to different types of
regulation. CPT-IA is inhibited by malonyl-CoA, whereas
a high-fat diet increases CPT-IA expression specifically in
the liver (5 ). Therefore, CPT-IA is the key enzyme in the
regulation of fatty acid oxidation. Twenty-two patients
with CPT-IA deficiency in 17 families have been reported
to date. All patients have CPT-IA deficiency (6 ), which
will subsequently be called “CPT-I”. To date, there has
been no report of a patient with CPT-IB deficiency.
Children with CPT-I deficiency usually present with
life-threatening attacks of fasting hypoketotic hypoglyce-
mia and coma during the first 2 years of life. Persistent
neurologic deficits are common. These children usually
do not have cardiac or skeletal muscle involvement.
However, four new cases were recently described that
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interestingly had myopathy with increased creatine ki-
nase or cardiac symptoms in the neonatal period (7 ). Once
diagnosed, patients can be treated by prevention of any
period of fasting that would require the use of fatty acids
as an energy source. In addition, because medium-chain
fatty acids bypass the carnitine cycle and enter the mid-
portion of the mitochondrial b-oxidation spiral directly,
dietary restriction of fat intake associated with supple-
mentation with medium-chain triacylglycerols (MCTs) is
considered to be helpful [for a review, see Ref. (8 )].
Except for increased free carnitine, the blood acylcar-
nitine profile from CPT-I-deficient individuals has been
considered unremarkable, with no pathologic acylcarni-
tine species detectable (9, 10). One preliminary report has
emphasized markedly reduced long-chain acylcarnitines
in CPT-I deficiency (11 ).
Because CPT-I deficiency may be amenable to treat-
ment, inclusion of new markers into electrospray ioniza-
tion–tandem mass spectrometry (ESI-MS/MS)-based new-
born screening is desirable, both to estimate its incidence
and to allow for early diagnosis.
Materials and Methods
materials
l-[2H3]Carnitine and l-[
2H3]palmitoylcarnitine from
Cambridge Isotope Laboratories were obtained from Pro-
mochem. Filter paper (S&S 2992) was purchased from
Schleicher & Schu¨ell. Nunc 96-well microtiter plates were
obtained from Labor Schubert. Methanol, acetonitrile, and
formic acid (HPLC grade) were from Merck. Butanolic
hydrochloric acid was prepared by saturating dry HPLC-
grade 1-butanol with HCl gas.
instruments
The following devices were used: a BSD 200 automated
punching device (BSD Technologies International); a Tit-
ramax 1000 orbital shaker (Heidolph); a Savant Model
SC210 A SpeedVac Plus centrifugal evaporator (Life Sci-
ences); and an API 365 ESI-MS/MS system equipped with
a TurboIon spray device, Series 200 lp HPLC pump, and
Series 200 autosampler (PE-SCIEX).
Instrument control and data acquisition were per-
formed by the software LC sample control and LC tune
1.3 (PE-SCIEX) on a personal computer (Power Macintosh
9600/200). Signal intensities and the ratios of the analytes
to their respective internal standards were calculated
from the total-ion chromatograms by an Apple script that
is part of the Mac System D1-7.5.5 Neonatal Script 1.1c.
Statistical analysis was performed with SPSS, Ver.
10.0.5 software (SPSS).
samples
Whole blood was drawn by heel prick or venipuncture
and dried on filter paper. A total of 177 842 samples from
the central Bavarian newborn-screening program were
analyzed during 18 months, which accounted for .98% of
the Bavarian newborn population of that time period. For
participation in the Bavarian newborn-screening program
covering an extended disease range, written consent of
the parents is required. Blood sampling is recommended
between 48 and 72 h of life: 50% of the samples were taken
within that time period, and 96% of the samples were
taken within the first 5 days of life. In addition, samples
from two patients with CPT-I deficiency were analyzed,
including the original newborn-screening filter cards.
methods
Free carnitine and acylcarnitines were analyzed by ESI-
MS/MS (12 ) using a modification of the methods de-
scribed by Chace et al. (13 ) and Millington et al. (14 ).
From the dried-blood samples, 3.2-mm (1/8-inch) spots
were punched out and transferred to a 96-well microtiter
plate. To each spot, 50 mL of internal standard solution
containing 37.5 pmol of l-[2H3]carnitine and 7.5 pmol of
l-[2H3]palmitoylcarnitine was added. After 5 min, 150 mL
of methanol was added. The plate was then covered and
shaken for 30 min at room temperature on an orbital
shaker; 150 mL of the methanolic extract was then trans-
ferred to a second microtiter plate and evaporated to
dryness in a Teflon-lined centrifugal evaporator. The
acylcarnitines and free carnitine were derivatized to their
corresponding butyl esters with 50 mL of saturated butan-
olic hydrochloric acid. The plate was sealed with polysty-
rene-coated aluminum foil and heated at 65 °C for 20 min.
After cooling, the solvent was evaporated in a centrifugal
evaporator. The residue was redissolved in 100 mL of
acetonitrile–water–formic acid (50:50:0.025 by volume)
before analysis. A 35-mL aliquot of each sample was
introduced at a flow rate of 100 mL/min into the ioniza-
tion chamber. Free carnitine and acylcarnitines were mea-
sured by positive precursor ion scan of 85 Da (scan range,
200–500 Da) using the following settings: ion spray volt-
age, 5500 V; orifice voltage, 15 V; collision energy, 38 V.
The collision gas was set to a pressure of 2.1 3 1025 Torr.
Mass fragment data were collected in a 2.5-min window.
Mass resolution was defined by a step size of 1 atomic
mass unit (amu) and a dwell time of 20 ms. For calculation
of the concentration of stearoylcarnitine, l-[2H3]palmi-
toylcarnitine was used as reference.
Results
patients
Patient 1 was the fifth child of consanguineous parents.
Two siblings had died at the 2nd and 5th day of life,
respectively; therefore, newborn screening of this patient
was performed at the age of 12 and 65 h. At admission to
our hospital at the age of 65 h, the boy appeared clinically
well. However, he developed generalized seizures a few
hours later. The electroencephalogram (EEG) was abnor-
mal. In addition, renal tubular acidosis was observed. At
the time of transfer, plasma glucose, ammonia, amino-
transferase activities, and creatine kinase were within the
appropriate reference intervals. The patient was placed on
a high-carbohydrate, low-fat diet with MCT supplemen-
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tation. The EEG normalized, and anticonvulsive treat-
ment could be withdrawn. Renal tubular acidosis re-
solved. At the age of 15 months, the boy showed normal
neurologic development.
Patient 2 was the first child of nonconsanguineous
parents. The boy had been clinically asymptomatic until
the age of 9 months. He came to medical attention during
an episode of somnolence attributable to mild nonketotic
hypoglycemia (glucose, 2 mmol/L). After 5 days of en-
cephalopathy with depressed EEG activity, the patient
fully recovered. Aminotransferase activities were in-
creased (aspartate aminotransferase, 275 U/L; alanine
aminotransferase, 362 U/L), whereas creatine kinase and
ammonia were within the appropriate reference intervals.
The patient remained well on a low long-chain fat diet
supplemented with MCTs.
Patient 3 was the product of an incestuous relationship
in a family of Asian origin. Neonatal adaptation was
uneventful. The child was admitted to the hospital for
failure to thrive at age 2 months, but no specific diagnosis
was made and the child was discharged. At age 5 months,
he was found in a comatose state without preceding
illness. While being taken to the emergency department,
he had generalized convulsions. The liver was moderately
enlarged. Severe nonketotic hypoglycemia was found
(,0.5 mmol/L). The child recovered consciousness over
several days, but the EEG showed persistence of epileptic
discharges. The child was placed on a MCT-enriched diet.
There was sporadic recurrence of seizures for a few
months followed by complete remission. Psychomotor
development was, however, moderately delayed. Under
the MCT-enriched diet, the child’s physical growth was
good with catch-up growth, and he was in excellent
physical condition at age 18 months.
CPT-I deficiency was confirmed by enzyme assay in
cultured skin fibroblasts from all three patients: CPT-I
activity was 0.00 nmol/min z mg protein in patient 1, 0.04
nmol/min z mg protein in patient 2, and 0.00 nmol/
min z mg protein in patient 3. The mean (6 SD) activity in
cultured skin fibroblasts from 12 controls was 0.58 6 0.26
nmol/min z mg protein.
linearity
For the determination of linearity, precision, and recov-
ery, blood from a healthy volunteer was supplemented
with increasing amounts of free carnitine, palmitoylcarni-
tine, and stearoylcarnitine. For regression analysis, the
ratio of the analyte signal vs internal standard signal was
plotted against the analyte concentration. Values from 10
consecutive days were calculated. The mean slope, y-
intercept, and coefficient of linear regression (r2) were
0.05, 3.29 mmol/L, and 0.955 for free carnitine (C0); 0.082,
0.20 mmol/L, and 0.980 for palmitoylcarnitine (C16); and
0.085, 0.13 mmol/L, and 0.975 for stearoylcarnitine (C18),
respectively. The calibration curves were linear at least up
to 192 mmol/L (C0), 26 mmol/L (C16), and 25 mmol/L
(C18), respectively.
precision and recovery
The intraassay precision was determined with 20 repeat
samples in one analytical run. The mean 6 SD concentra-
tions (CVs) were 48.4 6 3.16 mmol/L (6.5%) for free
carnitine (C0), 10.5 6 0.67 mmol/L (6.4%) for palmitoyl-
carnitine (C16), and 0.42 6 0.04 mmol/L (9.5%) for
stearoylcarnitine (C18), respectively. The interassay pre-
cision and recovery data (on 20 consecutive days) were
determined at two different concentrations for each ana-
lyte. The mean 6 SD concentrations (CVs) were 17.0 6 2.7
(16%) and 57.3 6 8.0 mmol/L (14%) for free carnitine (C0),
Fig. 1. Mean values for the C0/(C16 1 C18) ratio for different birth
weight classes.
Age, 2–5 days. The boxes represent the interquartile range (25th–75th centiles);
the horizontal black bar represents the median; the error bars indicate the 95%
confidence interval of the mean.
Fig. 2. Mean values for the C0/(C16 1 C18) ratio for different age
groups.
Birth weight .2500 g. The boxes represent the interquartile range (25th–75th
centiles); the horizontal black bar represents the median; the error bars
represent the 95% confidence interval of the mean.
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0.60 6 0.10 (17%) and 8.2 6 1.6 mmol/L (19%) for
palmitoylcarnitine (C16), and 0.52 6 0.07 (13%) and 8.4 6
1.0 mmol/L (12%) for stearoylcarnitine (C18), respectively.
The mean recoveries were 92.9% for free carnitine (C0),
82.6% for palmitoylcarnitine (C16), and 97.3% for
stearoylcarnitine (C18), respectively.
analytical sensitivity and detection limit
The detection limit (signal 1 3 SD of a sample free of
analyte) of the assay was 1.15 mmol/L for free carnitine
(C0), 0.03 mmol/L for palmitoylcarnitine (C16), and 0.01
mmol/L for stearoylcarnitine (C18). The quantification
limit (signal 1 6 SD of a sample free of analyte) was 1.92
mmol/L for free carnitine (C0), 0.05 mmol/L for palmi-
toylcarnitine (C16), and 0.02 mmol/L for stearoylcarnitine
(C18).
diagnostic specificity
During 18 months, we analyzed samples from 177 842
newborns from the Bavarian newborn-screening pro-
gram. We diagnosed a patient with CPT-I deficiency, who
was the first to be detected prospectively by ESI-MS/MS
newborn screening. In addition, samples from two pa-
tients with CPT-I deficiency found in high-risk screening
were analyzed (samples at the time of diagnosis and the
original newborn-screening filter cards retrospectively).
Free carnitine (C0), palmitoylcarnitine (C16), and stearoyl-
carnitine (C18) are measured routinely within the new-
born-screening program. As a potential marker for CPT-I
deficiency, the ratio of free carnitine to the sum of
palmitoylcarnitine and stearoylcarnitine [C0/(C16 1
C18)] was also evaluated. Incidences of decreased concen-
trations of palmitoylcarnitine and stearoylcarnitine
(,0.1th centile) were still above the quantification limit
and could thus be quantified reliably. For the C0/(C16 1
C18) ratio, no significant difference was detected between
boys (n 5 69 796) and girls (n 5 64 782; means, 4.62 and
4.56, respectively; P 5 0.576; age at sampling, 2–5 days;
birth weight .2500 g). However, the ratio is dependent on
birth weight and age. There was a significant steady
decrease from newborns with a birth weight ,1000 g (n 5
369) to newborns with a birth weight .2500 g (n 5
110 580; age at sampling 2–5 days). The mean values were
10.03 and 4.55, respectively (P ,0.001; see Fig. 1). The
ratio also decreased significantly after 24 h of age [mean,
5.66 at age ,1 day (n 5 1653) and 4.59 at age 1–4 days
(n 5 143 185); P ,0.001] and increased strongly in the age
group 5–15 days [mean, 4.59 at age 1–4 days (n 5 143 185)
and 15.84 at age .15 days (n 5 1027); P , 0.001; Fig. 2].
The frequencies of abnormal concentrations of free
carnitine, palmitoylcarnitine, stearoylcarnitine, and the
C0/(C16 1 C18) ratio are shown in Table 1. Of a total of
177 842 samples, there were 164 with isolated decreased
palmitoylcarnitine concentrations or decreased palmitoyl-
and stearoylcarnitine concentrations. In addition, we
found increased concentrations of free carnitine in 27
samples from children with known carnitine supplemen-
tation, in 1 postoperative sample, in 1 sample from a child
with kidney agenesis, in 1 sample from a child with
mitochondrial DNA depletion syndrome, in 2 samples
from the newborn period of the first CPT-I patient to be
detected prospectively by ESI-MS/MS newborn-screen-
ing, and in 4 samples of two cases of prediagnosed CPT-I
deficiency. The frequency distributions for the Bavarian
newborn population of free carnitine, palmitoylcarnitine,
and the ratio C0/(C16 1 C18) are shown in Fig. 3. For the
assessment of reliable criteria and cutoff values for the
detection of patients with CPT-I deficiency, we retrospec-
tively calculated the specificity (number of true nega-
tives/sum of true negatives and false positives), the
sensitivity (number of true positives/sum of true posi-
tives and false negatives), and the positive predictive
Table 1. Concentrations and ranges (0.1–99.9th centile) for free carnitine (C0), palmitoylcarnitine (C16), stearoylcarnitine
(C18), and the ratio C0/(C16 1 C18) in the total screening population, in children with known carnitine supplementation,
in patients with CPT-I deficiency, and in selected cases.
C0, mmol/L C16, mmol/L C18, mmol/L C0/(C16 1 C18) n
Total 7–89 0.59–12.7 0.19–2.6 2.00–32.0 177 645
Low C16 (,0.1st centile) 3–39 0.07–0.59 0.03–1.2 2.4–61 164
Carnitine-supplemented 35–455 1.2–12.5 0.5–2.4 5–94 27
Postoperative 352 3.48 1.13 76 1
Kidney agenesis 73 0.50 0.12 118 1
Mitochondrial DNA depletion syndrome 118 1.05 0.44 79 1
Patient 1
2 h 75 0.16 0.09 300
3rd day 63 0.33 0.03 175
Patient 2
5th day 140 0.20 0.09 483
12 months 291 0.10 0.05 1940
Patient 3
5th day 83 0.15 0.09 346
7 months 118 0.10 0.03 908
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value (number of true positives/sum of true positives and
false positives) for various markers and combinations
(Table 2).
Discussion
In CPT-I deficiency, the conjugation of long-chain acyl-
CoA substrates to carnitine is absent. The major deviation
to be expected in the metabolic pattern is decreased
long-chain acylcarnitines, especially palmitoylcarnitine
and stearoylcarnitine. Because of the impaired conjuga-
tion of fatty acids with carnitine, the concentrations of
both free and total carnitine increase. The muscle is
quantitatively responsible for a high proportion of total
b-oxidation of fatty acids in the body. Therefore, muscle
CPT-I might contribute to the generation of substantial
amounts of, e.g., palmitoylcarnitine. However, data from
Al Aqeel and Rashed (11 ) and Sim et al. (15 ) as well as our
observations support the hypothesis that muscle CPT-I
does not significantly influence blood concentrations of
palmitoylcarnitine. It has recently been hypothesized that
the higher expression of the liver isoform of CPT-I in fetal
heart compared with the expression of the muscle isoform
of CPT-I may lead to cardiac problems in the neonate with
CPT-I deficiency (16 ). An increased concentration of
plasma free carnitine has been thought to be the only
diagnostic marker metabolite for CPT-I deficiency (17 ).
Sim et al. (15 ) correctly suggested in a recently published
report that an isolated increase in free carnitine in an
apparently healthy term neonate warrants further inves-
tigation to exclude CPT-I deficiency. However, our data
show that in the newborn period free carnitine concentra-
tions in CPT-I-deficient patients can still be within the
interval reference (Table 1). It needs to be emphasized that
quantification of free carnitine in blood spots is not
reliable because of the various decomposition character-
istics of acylcarnitines, in particular of acetylcarnitine as
recently described by Johnson (18 ), who showed that 30%
of acetylcarnitine, 8% of decanoylcarnitine, and 6% of
octadecanoylcarnitine butanolyze in 15 min when the
dried extracts are heated in 3 mol/L HCl in n-butanol at
65 °C. Even taking into account the hydrolysis of labeled
and unlabeled acylcarnitines, the applied ratio of C0/(C16
1 C18) is sensitive enough to define cutoff values and to
reliably allow for diagnosis of CPT-I deficiency.
In healthy individuals, carnitine status is dependent on
nutritional state, age, and birth weight (19–21). Signifi-
cantly increased serum free carnitine has been observed in
patients with idiopathic hypertrophic cardiomyopathy
attributable to decreased myocardial uptake (22 ). There-
fore, increased free carnitine alone is not a specific feature
suitable for the detection of patients with CPT-I defi-
ciency. Long-chain acylcarnitines seem to be a better
marker because they are already decreased in CPT-I
patients at birth (Table 1). As shown in Tables 1 and 2 and
Fig. 3. Frequency distributions of free carnitine (A), palmitoylcarnitine
(B), and the C0/(C16 1 C18) ratio (C).
Six samples from the three CPT-I-deficient patients (F) and samples from
individuals on carnitine supplementation (3) are specially depicted (see also
Table 1). P1a and P1b, samples from patient 1 taken at 2 h and on 3rd day,
respectively; P2a and P2b, samples from patient 2 taken at 5th day and 12
months, respectively; P3a and and P3b, samples from patient 3 taken at 5th day
and 7 months, respectively
Table 2. Recalculated values for specificity, sensitivity, and positive predictive value for markers for CPT-I deficiency.a
TNb FN TP FP
Specificity,
%
Sensitivity,
%
Positive predictive
value, %
C0 .99.9th centile 177 660 2 1 178 99.90 33.3 0.56
C16 ,0.1th centile 177 677 0 3 161 99.91 100 1.86
C16 ,0.1th centile and
C18 ,0.1th centile
177 773 0 3 65 99.96 100 4.62
C0/(C16 1 C18) .100 177 838 0 3 0 100 100 100
a Total number of samples was 177 842.
b TN, true negative; FN, false negative; TP, true positive; FP, false positive.
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in Fig. 3, use of the ratio of free carnitine to the sum of
palmitoylcarnitine and stearoylcarnitine [C0/(C16 1
C18)] strongly increases specificity and especially the
positive predictive value. When decreased concentrations
of long-chain acylcarnitines are used as a single marker,
exact birth weight- and age-related cutoff values need to
be established to maintain acceptable sensitivity and
specificity.
The reliability of the ratio C0/(C16 1 C18) is depen-
dent on the accurate measurement of low concentrations
of long-chain acylcarnitines (especially palmitoyl- and
stearoylcarnitine). With the cutoff value set to 100, the
C0/(C16 1 C18) ratio can reliably distinguish between
samples from CPT-I-deficient patients on the one hand
and samples from healthy individuals, samples from
patients on carnitine supplementation, and samples from
patients with severe diseases that potentially affect carni-
tine and/or fatty acid metabolism on the other hand.
Early detection of CPT-I by newborn screening might
prevent both a neonatal life-threatening metabolic decom-
pensation and commonly observed neurologic deficits.
We wish to thank Dr. R.J.A. Wanders (University Hospital
Amsterdam, Laboratory for Genetic Metabolic Diseases,
Amsterdam, The Netherlands) for assaying CPT-I in cul-
tured skin fibroblasts. We thank Dr. E. Lainka (University
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ing the blood samples and clinical information of one
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We analyzed the urinary acylglycine excretion in
26 patients with mitochondrial energy metabolism
disorders and in 55 patients with organic acidurias
by electrospray tandem mass spectrometry (ESI-
MS/MS), monitoring precursor ions of m/z 90. Uri-
nary concentrations of the different acylglycines
were quantified using deuterated internal stan-
dards. Normal values for the most important acylg-
lycines were established. In MCAD and MAD (neo-
natal form) deficiencies, typical excretion patterns
of urinary acylglycines were found in all the sam-
ples. In isovaleric aciduria, propionic aciduria, and
3-methylcrotonylglycinuria typical glycine conju-
gates were always found. Methylmalonic aciduria
(mutase deficiency), multiple carboxylase defi-
ciency, and 3-hydroxy-3-methylglutaric aciduria re-
vealed pathological acylglycine profiles, even if not
specific for the disease. In all these diseases acyl-
glycine excretion seems to be less influenced by the
clinical status than organic acid excretion. This
method is a useful diagnostic tool for these meta-
bolic disorders, complementary to organic acids
and acylcarnitine profiles. © 2000 Academic Press
Key Words: acylglycine; ESI-MS/MS; fatty acid ox-
idation; organic aciduria.
Glycine conjugation, an important detoxification
system of the human body, takes place mainly in the
liver (1). The mitochondrial enzyme glycine-N-acy-
lase is responsible for conjugation of glycine with
exogenous compounds to enhance their excretion in
urine (1–3). Glycine conjugation is also an effective
detoxification system for preventing accumulation of
acyl-CoA esters in several inherited metabolic dis-
orders. Acylglycines in urine are the direct expres-
sion of accumulation of the correspondent acyl-CoA
esters in the mitochondrion (3). The study of acyl-
glycines in urine can be diagnostic for inherited met-
abolic disorders, such as the defects in fatty acid
oxidation (acyl-CoA dehydrogenases) and leucine ca-
tabolism (isovaleryl-CoA dehydrogenase, methyl-
crotonyl-CoA carboxylase). Furthermore, other en-
zyme defects involved in the catabolism of
isoleucine, valine, and lysine (propionyl-CoA carbox-
ylase, glutaryl-CoA dehydrogenase) are character-
ized by an accumulation of specific glycine conju-
gates. Common to all these disorders are life-
threatening, “intoxication-like” metabolic crises,
sometimes with the features of Reye-like syn-
dromes. Specific metabolites, reflecting directly the
enzymatic block and indirectly the intermediate me-
tabolism impairment, are detectable in urine and
blood during crisis. Urinary organic acid analysis
and free and total carnitine in plasma are the main
diagnostic tools in these situations, followed by the
study of blood and urine acylcarnitine profiles. In
the absence of metabolic decompensation, when the
1 These authors contributed equally to this paper.
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Clinical Chemistry and Biochemistry, Department of Pediatrics,
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subject is doing well, these parameters are often not
informative, and early diagnosis is essential to treat
the disease and prevent a metabolic crisis.
So far, urinary acylglycine excretion was studied
by gas chromatography mass spectrometry (GC/MS)
(4,5) and liquid secondary ion tandem mass spec-
trometry (LSI-MS/MS) (6) mainly in medium-chain
acyl-CoA dehydrogenase deficiency. The aim of the
present study was to analyze the urinary acylglycine
excretion pattern in a wide spectrum of inborn er-
rors of metabolism by means of electrospray tandem
mass spectrometry (ESI-MS/MS).
METHODS
Subjects. We analyzed 235 urine samples of 81
patients (aged a few days to 30 years) affected by 14
different metabolic diseases (Table 1). The samples
were collected from patients with known diagnoses,
in different clinical situations, and studied retro-
spectively. Fifty-four urine samples from children,
aged a few days to 15 years, were analyzed as con-
trols. No significant age-dependent difference in
acylglycine excretion was observed. Organic acid
profiles were normal in all the control samples.
Internal standard solution. Fifty microliters
of internal standard solution contained 150 ng
d3-acetylglycine, 20 ng d3-propionylglycine, 30 ng
d7-butyrylglycine, 30 ng d9-valerylglycine, and
20 ng d3-hexanoylglycine (in methanol). All the
internal standards were 2H-labeled in the acyl
group. The deuterated acylglycines were pur-
chased from H. ten Brink, Academic Hospital,
Amsterdam.
Preparation of acylglycine-methylesters. All the
urine samples were derivatized to methylesters.
Other derivatization procedures were used only for
structure elucidation of unknown peaks. The
amount of urine used for acylglycine analysis de-
pended on the creatinine concentration (see Table
2). Fifty microliters of internal standard solution
were added to the urine sample, which was subse-
quently dried in a SpeedVac concentrator (Savant,
Farmingdale, NY) at 42°C and treated with 50 ml of
3 M methanolic HCl (Supelco, Bellefonte, PA) at
65°C for 15 min in a screw-capped vial. After evap-
oration of the solvent, the residue was reconstituted
in 100 ml of methanol/water (50/50, vol/vol) contain-
ing 0.1% acetic acid.
TABLE 1
Summary of Patients and Samples Analyzed in Different Disorders
Disease Number of patients Number of samples
Mitochondrial energy metabolism disorders
Multiple acyl-CoA dehydrogenase deficiency (MAD) or glutaric aciduria type II
(ETF, ETF-dehydrogenase deficiency)
Neonatal form 7 29
Late onset form 2 2
Fatty acid oxidation defects:
Medium-chain acyl-CoA dehydrogenase deficiency (MCAD) 5 15
Long-/very-long-chain acyl-CoA dehydrogenase deficiency (LCAD/VLCAD) 7 10
Short-chain acyl-CoA dehydrogenase deficiency (SCAD) 1 9
Long-chain hydroxyacyl-CoA dehydrogenase deficiency (LCHAD) 1 1
Short-chain hydroxyacyl-CoA dehydrogenase deficiency (SCHAD) 1 1
Carnitine-palmitoyl-transferase II deficiency (CPT II) 2 5
Organic acidurias
Isovaleric aciduria, isovaleryl-CoA dehydrogenase deficiency (IVA) 2 5
Propionic aciduria, propionyl-CoA carboxylase deficiency (PA) 16 47
Methylmalonic aciduria (MMA)
Methylmalonyl-CoA mutase deficiency 15 48
Cobalamin C deficiency 6 13
3-Methylcrotonyl glycinuria, 3-methylcrotonyl-CoA carboxylase deficiency (MCG) 1 1
Multiple carboxylase deficiency (MCD)
Holocarboxylase synthetase deficiency 2 7
Biotinidase deficiency 3 3
3-Hydroxy-3-methylglutaric aciduria (3-OH-3-methylglutaryl-CoA lyase deficiency) 3 10
Glutaric aciduria type I 7 29
Total 81 235
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Preparation of acylglycine-butylesters. The same
procedure as for acylglycine-methylesters was used
for acylglycine-butylesters. Instead of methanolic
HCl, 3 M butanolic HCl (Regis, Morton Grove, IL)
was used as derivatization reagent.
Preparation of acetylated acylglycine-butylesters.
The urine samples were derivatized to butylesters
prior to acetylation of the hydroxy groups. The bu-
tylated acylglycine samples were dried in a Speed-
Vac concentrator at 42°C. The residue was reconsti-
tuted in 100 ml of acetic anhydride/pyridine (50/50,
vol/vol). The sample was allowed to react at room
temperature for 60 min. After evaporation of the
solvent, the residue was redissolved in 100 ml of
methanol/water (50/50, vol/vol) containing 0.1% ace-
tic acid.
Mass spectrometry. ESI-MS/MS was carried out
on a Perkin-Elmer SCIEX API 365 LC/MS/MS sys-
tem (Toronto, Canada). Samples were infused into
the electrospray ion source via a 50 mm i.d. fused
silica transfer line using a Kontron Model 420 HPLC
pump (Rotkreuz, Switzerland) at 20 ml/min. The
mobile phase used for all experiments was metha-
nol/water (50/50, vol/vol) containing 0.1% acetic
acid. The sample solution (20 ml) was injected with a
Rheodyne 8125 injector valve (Cotati, CA) equipped
with a 20-ml sample loop. Nitrogen was used as the
collision gas at a pressure of 7 mTorr. Positive-ion
electrospray MS/MS was performed at an orifice
voltage of 0 V and the collision energy was set to 13
eV. For acylglycine-methylester profiles, the MS/MS
method proposed by Millington et al. (6) was applied;
precursor ions of m/z 90 were monitored in the range
m/z 125–300 with step size 0.1 (4 s per scan). Addi-
tionally, precursor ions of m/z 91 were monitored in
the range m/z 132–138, 164–170, and 180–186, with
step size 0.1 (0.6 s per scan). Precursor ion scans of
m/z 91 are performed for analysis of the isotopically
labeled standards d3-acetylglycine (m/z 135), d7-bu-
tyrylglycine (m/z 167), and d9-valerylglycine (m/z
183), all of which have a deuterium atom at C-2 of
the acyl group. The deuterium atom participates in
the formation of the daughter ion at m/z 91 (6). By
alternatively switching the scan function from par-
ents of m/z 90 to parents of m/z 91, the internal
standards were acquired simultaneously from the
urine sample. Fifteen to 20 scans were averaged to
obtain the final spectrum.
For acylglycine-butylester profiles and for acety-
lated acylglycine-butylester profiles, precursor ions
of m/z 132 were monitored in the range m/z 170–450
with step size 0.1 (5 s per scan).
For analyzing daughter ions of the corresponding
masses, the same conditions as those for precursor
ion scans were applied.
A solution of 7.6 mM acetylglycine, 6.9 mM pro-
pionylglycine, 1.7 mM butyrylglycine, 9.2 mM valeryl-
glycine, and 6.4 mM hexanoylglycine in methanol
was derivatized to acylglycine-methylesters accord-
ing to the procedure described above: this solution
was used for mass spectrometer tuning.
Creatinine concentration. Creatinine concentra-
tions were measured by the Jaffe´-modified kinetic
method (7) by a Beckman Synchron CX5 analyzer
(Brea, CA).
Quantification of acylglycine-methylesters. The
acylglycine-methylester profiles are quantified by
comparing peak heights of isotopically labeled acyl-
glycines with natural acylglycines (stable isotope
dilution method). All concentrations are expressed
as millimole per mole of creatinine. Acylglycines for
which no deuterated internal standards were avail-
able were quantified by using the standard with the
closest molecular mass.
RESULTS
Structure elucidation. In all the samples acyl-
glycines were analyzed after derivatization to meth-
ylesters. Most of the peaks detected in urine corre-
spond to acylglycines. Some of them, however, cor-
respond to other compounds which yield also m/z 90
without belonging to acylglycines. In order to distin-
guish between these compounds and acylglycines,
various tandem mass spectrometric experiments
were performed. (i) In addition to acylglycine-meth-
ylesters, acylglycine-butylesters were prepared. Bu-
tylester samples were analyzed by monitoring the
precursor ions of m/z 132. Candidates for acylgly-
TABLE 2
Creatinine-Dependent Amount of Urine Used
for Acylglycine Analysis
Creatinine concentration Volume of urine
,1.0 mmol/L 200 ml
1.0–2.0 mmol/L 100 ml
2.1–3.4 mmol/L 60 ml
3.5–4.9 mmol/L 40 ml
5.0–6.9 mmol/L 30 ml
7.0–9.0 mmol/L 20 ml
.9.0 mmol/L 10 ml
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cines should exhibit a molecular weight shift of 142
amu compared to the corresponding methylester (di-
carboxylic acylglycines: 184 amu). Comparison of
the acylglycine-methylester and the acylglycine-bu-
tylester profiles of the same sample allows identifi-
cation of the peaks that do not correspond to glycine
conjugates. (ii) Hydroxy-acylglycines were distin-
guished from other acylglycines by acetylation of the
esterified sample. After acetylation, hydroxy-acyl-
glycines exhibit a molecular weight shift of 142 amu
compared to the corresponding esterified acylgly-
cines. (iii) Acquisition of daughter ion scan spectra of
acylglycines was performed to obtain information
about the structure of the compounds. Daughter ion
spectra of the acylglycine-methylester ions [M1H]1
usually exhibit pronounced fragment peaks at m/z
90, corresponding to the loss of the acyl group as
ketene (6). In addition, the loss of methanol (232
amu) and of 89 amu from [M1H]1 yields fragments
with high intensity.
Table 3 lists the corresponding protonated molec-
ular weights of the acylglycine-methylesters. The
different structures were assigned with the help of
literature data and by executing the experiments
described above. It must be mentioned, however,
that isomeric structures (for example valeryl- and
isovalerylglycine) cannot be distinguished; neither
could the position of the hydroxy group in the acyl-
glycines be determined by our method.
Urine analysis. The analysis of control urine
samples showed that many acylglycines were detect-
able in small amounts (Fig. 1A). The most intense
signal is ascribed to ACG. C4-G, C5-G, and HG are
also present but PG, MCG, PPG, and SG were never
detected. A significant peak with high intensity at
m/z 150, corresponding to homocysteine (Hcy), is
always detected in the profiles. Previous work dem-
onstrated the presence of reduced homocysteine in
plasma in low concentrations (8). A fragment ion at
m/z 90 is produced by collision-induced dissociation
(CID) from protonated molecular ions of homocys-
teine (9). In urine samples this amino acid is there-
fore analyzed simultaneously with the acylglycines.
Low-intensity signals corresponding to HBG (m/z
176) and PAG (m/z 208) can be detected; other sig-
nals (m/z 220, 234, 248) are not glycine-conjugated
compounds. Table 4 shows the acylglycine patterns
found in the pathological samples by ESI-MS/MS com-
pared to the literature reports about other methods.
It must be noted that the most prominent acyl-
glycines in urine are hippuric acid and 4-hydroxyhip-
TABLE 3
Masses and Abbreviations of Protonated Acylglycines
Mass (amu) Abbreviation Acylglycine-methylester
132 ACG Acetylglycine
135 d3-ACG d3-Acetylglycine (internal standard)
146 PG Propionylglycine
149 d3-PG d3-Propionylglycine (internal standard)
150a
160 BG, IBG, C4-G Butyrylglycine, isobutyrylglycine
167 d7-BG d7-Butyrylglycine (internal standard)
172 TG 2-Methylcrotonylglycine (tiglylglycine)
172 MCG 3-Methylcrotonylglycine (3,3-dimethylacryloylglycine)
174 IVG, MBG, C5-G Isovalerylglycine, 2-methylbutyrylglycine
176 HBG Hydroxybutyrylglycine
183 d9-VG d9-Valerylglycine (internal standard)
188 HG, MVG, C6-G Hexanoylglycine, 4-methylvalerylglycine
190 HVG Hydroxyvalerylglycine
191 d3-HG d3-Hexanoylglycine (internal standard)
200 C7:1-G Heptenoylglycine
202 MHG, C7-G 4-Methylhexanoylglycine, heptanoylglycine
208 PAG Phenylacetylglycine
218 GG Glutarylglycine
222 PPG Phenylpropionylglycine
232 7-HOG, 8-HOG 7-Hydroxyoctanoylglycine, 8-hydroxyoctanoylglycine
260 SG Suberylglycine
a Hcy, homocysteine.
305ACYLGLYCINES ANALYZED BY ESI-MS/MS
61
FIG. 1. ESI-MS/MS urinary acylglycine profiles in controls and in different disorders. (Peaks marked with asterisk correspond to internal
standards. Unmarked peaks are not acylglycines).
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puric acid (1,2). Because of the lack of protons at
position 2 of the acyl group, these compounds cannot
be detected by the applied method (6).
Quantification of acylglycine concentrations in
control urine samples and in different diseases is
shown in Table 5.
Mitochondrial energy metabolism disorders.
Urine from patients with MCAD and MAD deficien-
cies showed typical patterns of acylglycine excretion
(Figs. 1B–1C). In MCAD patients (15 samples), HG,
PPG, and SG are the main metabolites excreted in
urine (Fig. 1B); C4-G, C5-G, C7-G, and HOG are also
detectable. We observed that the acylglycine profiles
are always pathological in MCAD, independent of
the clinical status. HG is always excreted in large
amounts and both HG and SG increase in the course
of the illness; PPG and HOG are often detectable in
the compensated state, and they are clearly elevated
during acute crises.
In urine samples from the SCAD-deficient patient
BG was not always elevated (Fig. 1D), being in the
normal range in 6 out of 9 samples.
LCAD/VLCAD (10 samples) as well as LCHAD (1
sample), SCHAD (1 sample), and CPT-II (5 sam-
ples)-deficient patients showed acylglycine excretion
comparable to that of normal subjects.
In MAD deficiency (neonatal form, 29 samples),
C4-G (BG and IBG) and C5-G (MBG and IVG) are the
most prominent acylglycines detected in urine (Fig.
1C), both in compensated and in decompensated
states. HG is often excreted in large amounts and its
excretion increases during illness along with C5-G.
Sometimes, especially when dicarboxylic aciduria is
elevated in the organic acid profiles, it is possible to
detect SG. Normal profiles were found in the late
onset form (2 samples).
Organic acidurias. All the samples from isova-
leric aciduria (5 samples), propionic aciduria (47
TABLE 4
Acylglycines Detected in Different Disorders
Disease
Detected by our method
(ESI-MS/MS)
Detected by other
methodsc References
MCAD deficiency C4-G BG 4,5,6,10,11,12,15,22
C5-G C5-G (MBG or IVG)
C6-G C6-G (HG and MVG)
C7-G (MHG) C7-G
HOG 7-HOG and 8-HOG
PPG PPG
SG SG
MAD deficiency C4-G C4-G (BG and IBG) 18,21,23
C5-G C5-G (MBG and IVG)
C6-G C6-G (HG)
SG SG
LCAD/VLCAD deficiency a — 18,19,22
SCAD deficiency C4-G (BG) BG 16,17,18,19,22
LCHAD deficiency a — 18,19
SCHAD deficiency a — 18,19,20
CPT-II deficiency a — 18,19
Isovaleric aciduria IVG IVG 2,12,24
Propionic aciduria PG PG 2,12
TG TG
3-Methylcrotonylglycinuria MCG MCG 2,13,24
Methylmalonic aciduria PG — 2
Multiple carboxylase deficiency PG PG 12
TG, MCG TG, MCG
3-OH-3-methylglutaric aciduria MCG MCG 12,24
Glutaric aciduria I GGb GG 3
Note. For abbreviations see Table 3.
a Normal acylglycine pattern comparable to healthy controls.
b Found in 8/29 samples from 4/7 patients.
c GC/MS, LSI-MS/MS.
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samples), and 3-methylcrotonylglycinuria (1 sam-
ple) showed the typical glycine conjugates in urine
in high concentrations (Fig. 1). IVG is excreted at a
very high level in isovaleric aciduria (Fig. 1E) com-
pared to unaffected children. In propionic aciduria,
PG is the main metabolite, followed by TG (Fig. 1F).
In methylmalonic aciduria (methylmalonyl-CoA mu-
tase deficiency) no specific markers were found but
all the 48 samples showed significant excretion of
PG (Fig. 1G), which increases in metabolic decom-
pensation. In some samples TG is also detected. In
methylcrotonylglycinuria (1 sample) MCG is de-
tected at high level (Fig. 1H). In 3-hydroxy-3-meth-
ylglutaric aciduria (10 samples), MCG is always ex-
creted in urine (Fig. 1I). MCG is also detectable
when organic acids are only mildly altered. In glu-
taric aciduria type I we observed normal acylglycine
profiles. Traces of GG are detectable in only 8 out of
29 examined samples (in 4 out of 7 patients), and
only in the decompensated state. In multiple carbox-
ylase deficiency (holocarboxylase synthetase defi-
ciency, 7 samples) the presence of PG is always
relevant, even when organic acid levels are not sig-
nificantly altered, and TG and/or MCG are usually
detectable, in highest amounts during acidotic cri-
ses. Biotinidase-deficient patients showed normal
acylglycine profiles (3 samples).
DISCUSSION
All the studies on acylglycines so far focused
mainly on MCAD deficiency, a relatively frequent
TABLE 5
Quantification of the Most Important Pathological Urinary Acylglycines in Different Disorders
Disease (n 5 number of samples) Acylglycines
Median Range
(mmol/mol creatinine)
MAD deficiency (n 5 29) C4-G (BG, IBG) 6.4 2.3–38.5
C5-G (MBG) 28.9 4.6–83.7
C6-G (HG) 3.6 0.8–44.4
MCAD deficiency (n 5 15) C6-G (HG) 31.4 11.8–103.2
C7-G 3.8 1.3–17.8
7-HOG or 8-HOG 1.1 0–16.7
PPG 2.6 0.8–306.6
SG 1.7 0–11.7
SCAD deficiency (n 5 9) BG 4.3 0.9–5.2
Isovaleric aciduria (n 5 5) IVG 3173.1 713.1–4760.4
Propionic aciduria (n 5 47) PG 46.0 2.8–1183.3
TG 2.0 0.1–81.9
3-Methylcrotonylglycinuria (n 5 1) MCG 40.8a
Methylmalonic aciduria (n 5 48) PG 1.8 0.1–80.6
Holocarboxylase synthetase deficiency (n 5 7) PG 1.0 0.5–311.1
TG, MCG 0.5 0.2–7.4
3-OH-3-methylglutaric aciduria (n 5 10) MCG 4.6 0.6–21.2
Controls (n 5 54) ACG 11.4 2.5–47.6
PG n.d. n.d.
C4-G 0.9 0–3.0
TG/MCG n.d. n.d.
C5-G 0.9 0.2–3.0
HBG 0.5 0–1.8
HG 0.7 0.2–2.4
C7-G n.d. n.d.
PAG 0.4 0–1.8
GG n.d. n.d.
PPG n.d. n.d.
7-HOG or 8-HOG n.d. n.d.
SG n.d. n.d.
Note. For abbreviations see Table 3. n.d., not detectable.
a Single value.
308 BONAFE´ ET AL.
64
disease that shows a typical pattern of glycine con-
jugates in blood and urine (4,10,11). They demon-
strate the sensitivity of this test also in patients
without acute illness (5). Organic acidurias were
also considered in some studies (2,12,13). The meth-
ods used until now were either GC/MS (4,5,10) or
LSI-MS/MS (6). In this study we present the analy-
sis of urinary acylglycine profiles in a wide spectrum
of disorders, including the main fatty acid oxidation
deficiencies and organic acidurias, by ESI-MS/MS.
MCAD deficiency is the most frequent fatty acid
oxidation disorder. MCAD catalyzes the oxidation of
C6-C14 fatty acids. Laboratory findings are as fol-
lows: low levels of free and total carnitine, as in all
the mitochondrial fatty acid metabolism defects;
massive C6-C10 dicarboxylic aciduria; elevated
plasma and urinary hexanoylcarnitine, octanoylcar-
nitine, and decenoylcarnitine, mainly during acute
episodes. Diagnosis is usually difficult during remis-
sion because the characteristic metabolites may not
be detectable. It is well known that urinary acylgly-
cine determination is an accurate test for the diag-
nosis of MCAD deficiency (4,5,10). HG and PPG are
characteristic, together with SG. HG and SG excre-
tion increases during the acute phase, PPG excre-
tion usually increases to a lesser degree (5,14).
Other acylglycines detected in urine of MCAD-defi-
cient patients are 4-MHG, 4-MVG, 7-HOG, and
8-HOG (15). After carnitine administration excre-
tion of acylcarnitines increases and that of acylgly-
cines decreases. In any case, glycine conjugation is
considered to be the major pathway of removal of C6
to C8 acyl-CoAs (5,14). For MCAD deficiency, we
confirmed the typical excretion of HG, PPG, and SG,
even when organic acid levels are only mildly or not
at all altered. With our method, HOG and MHG
were also detected in MCAD deficiency, especially
during illness. HOG is likely to be a product of
microsomal v–v1 oxidation and 4-MHG probably
originates from branched-chain fatty acid catabo-
lism. Most of the octanoyl-CoA is transformed to
octanoylcarnitine but the high sensitivity of the
method allows detection of even small amounts of
HOG.
SCAD deficiency is a very rare disorder of C4 fatty
acid oxidation, of which two forms are known, a
neonatal and an infantile form. The fasting state
usually shows normal glycemia and ketosis. Labora-
tory findings are increased urinary excretion of
2-methylsuccinic acid, butyrylcarnitine, and BG
(16,17). Dicarboxylic acids are usually only slightly
increased. All these metabolites are intermittently
detectable and the diagnosis can often be missed. In
SCAD deficiency, we found significantly elevated BG
only in a few samples.
LCAD/VLCAD deficiencies are characterized by
excretion of medium- and long-chain saturated di-
carboxylic acids and long-chain acylcarnitines. No
pathological acylglycine excretion has been de-
scribed up to now (18). LCHAD deficiency is charac-
terized by low levels of free and total carnitine,
excretion of 3-hydroxydicarboxylic acids in nearly
equimolar amounts of the saturated dicarboxylic ac-
ids, and long-chain acylcarnitines. SCHAD defi-
ciency is a rare disorder of short-chain hydroxy fatty
acid oxidation, and no pathological acylglycine ex-
cretion has so far been described (18–20). The de-
fects in the transport of fatty acids into the mito-
chondria are carnitine uptake defect (CUD),
carnitine palmitoyl transferase type I (CPT-I), car-
nitine translocase (TRANS), and carnitine palmitoyl
transferase type II (CPT-II) deficiencies. Apart from
CPT-II, these diseases are all associated with fast-
ing hypoketotic hypoglycemia; no dicarboxylic acid-
uria nor pathological acylglycine excretion is ex-
pected as no accumulation of acyl-CoA esters occurs
in the mitochondria (19). We confirmed, even if in a
limited number of patients, that in LCAD/VLCAD,
LCHAD, SCHAD, and in fatty acid transport defects
(CPT-II) no pathological acylglycine excretion was
detectable.
Multiple acyl-CoA dehydrogenase (MAD) defi-
ciency, or glutaric aciduria type II, is a defect of
electron transfer flavoprotein (ETF) or of electron
transfer flavoprotein dehydrogenase (ETF-DH). All
the mitochondrial flavin-containing acyl-CoA dehy-
drogenases are affected: long-, medium-, short-chain
acyl-CoA dehydrogenases, isovaleryl-CoA dehydro-
genase, 2-methylbutyryl-CoA dehydrogenase, glu-
taryl-CoA dehydrogenase, dimethylglycine dehydro-
genase, and sarcosine dehydrogenase. Fatty acid
and branched-chain amino acid metabolisms are
both affected. Typical metabolites excreted in this
disorder are medium-chain dicarboxylic acid, ethyl-
malonic acid, methylsuccinic acid, glutarate, 2-hy-
droxyglutarate, octanoylcarnitine, glutarylcarni-
tine, butyrylcarnitine, isovalerylcarnitine, C4-G
(BG, IBG), IVG or MBG, HG, and SG (18,21). Diag-
nosis is difficult, especially in late-onset forms, be-
cause the organic acid profiles are intermittently
altered. All the MAD deficiency samples from the
neonatal form were pathological, no matter what the
clinical status of the patient was at the time of urine
collection. The same acylglycine excretion pattern
309ACYLGLYCINES ANALYZED BY ESI-MS/MS
65
was found with and without riboflavin administra-
tion. The two samples from the late-onset form
showed normal acylglycine profiles.
Organic acidurias lead to accumulation of organic
acids in body fluids, resulting in disturbance of the
acid-base balance and the intracellular biochemical
pathways. The acute toxicity of organic acids during
attacks leads to cerebral suffering and damage but
chronic toxicity also leads to progressive neurologic
impairment. The diagnosis is usually based on uri-
nary organic acid analysis during decompensation.
It is known that some metabolites accumulating
in these diseases are conjugated efficiently with gly-
cine: isovaleryl-CoA, propionyl-CoA, tiglyl-CoA, and
3-methylcrotonyl-CoA are all substrates of the en-
zyme glycine-N-acylase (2). Isovaleryl-CoA has a
very high affinity for the enzyme, which is always
overwhelmed. Thus, isovalerylglycine is always
present in the urine of isovaleryl-CoA dehydroge-
nase-deficient patients, reaching levels thousands of
times those in normal controls (Table 5). Glycine
conjugation is the main detoxification system in this
disease, followed by isovalerylcarnitine production.
In propionic aciduria, propionyl-CoA is excreted in
high amounts as free propionic acid and in small
amounts as propionylglycine. Tiglyl-CoA has the
highest affinity for the enzyme and tiglylglycine is
found under three conditions: 3-methylcrotonylglyc-
inuria, propionic aciduria, and b-ketothiolase defi-
ciency. In 3-methylcrotonylglycinuria, the main me-
tabolite derived from methylcrotonyl-CoA is
3-hydroxyisovaleric acid which is excreted as 3-hy-
droxyisovaleryl-carnitine while a significant amount
is assumed to be transformed to MCG; the excretion
of 3-methylcrotonylglycine is enhanced by glycine
supplementation (13). Methylmalonyl-CoA is not a
substrate of the conjugating enzyme, therefore no
specific acylglycine excretion is expected in methyl-
malonic aciduria (2). However, PG is always detect-
able in urine from mutase-deficient patients, being a
possible marker for this disease.
In 3-hydroxy-3-methylglutaric aciduria the leu-
cine catabolism and ketone body synthesis are
impaired. The following metabolites are derived
from 3-hydroxy-3-methylglutaryl-CoA: 3-hydroxy-3-
methylglutaric acid (formed by hydrolysis), which is
always present in urine; 3-methylglutaconic acid
(formed by reverse reaction of 3-methylglutaconyl-
CoA hydratase); 3-methylglutaric acid (from hydro-
genation of 3-methylglutaconic acid). Another me-
tabolite is 3-methylcrotonyl-CoA, which is hydrated
to 3-hydroxyisovaleric acid or conjugated with gly-
cine to MCG, which is always present in the urine
samples studied.
Glutaric aciduria type I is characterized by accu-
mulation of glutaryl-CoA due to the lack of the en-
zyme glutaryl-CoA dehydrogenase. Glycine conjuga-
tion of glutaric acid occurs, even if this is not the
main metabolic pathway. In our study traces of GG
were detected in 8 out of 29 urine samples from 4 out
of 7 patients with glutaric aciduria type I, and only
when organic acid profiles were also altered.
Multiple carboxylase deficiency is caused by holo-
carboxylase synthetase deficiency or by biotinidase
deficiency. In this disease four biotin-dependent en-
zymes are affected: propionyl-CoA carboxylase,
3-methylcrotonyl-CoA carboxylase, pyruvate car-
boxylase, and acetyl-CoA carboxylase. The meta-
bolic pathways of gluconeogenesis, fatty acid synthe-
sis, and amino acid catabolism are disturbed. As a
consequence, the expected glycine conjugates are
PG, TG, and MCG, which were detected in our sam-
ples from holocarboxylase synthetase-deficient pa-
tients. Biotinidase-deficient patients showed normal
acylglycine profiles.
In conclusion, urinary acylglycine analysis by
ESI-MS/MS is a powerful diagnostic tool for some
mitochondrial energy metabolism defects and or-
ganic acidurias. For MAD and MCAD deficiencies,
acylglycines are always informative because their
excretion is less influenced by the clinical status
than the excretion of organic acids. For other dis-
eases the excretion pattern of acylglycine is not spe-
cific but there is always a pathological profile to
indicate a metabolic disorder. In fact, PG is always
present in methylmalonic aciduria and in holocar-
boxylase synthetase deficiency, and MCG is con-
stantly present in 3-hydroxy-3-methylglutaric acid-
uria. Further investigations should be done in order
to define the acylglycine excretion pattern in SCAD
deficiency.
The applied method is noninvasive, fast, and sen-
sitive for very low concentrations of acylglycines in
random urine samples. Therefore, it can be suitable
for the selective screening of diseases such as MAD
and MCAD deficiencies, isovaleric and propionic aci-
durias, and 3-methylcrotonylglycinuria. 3-Hydroxy-
3-methylglutaric aciduria, multiple carboxylase de-
ficiency, and methylmalonic aciduria can also be
suspected from the presence of abnormal glycine
conjugates. Urinary acylglycine measurement by
ESI-MS/MS should be considered as a fast and use-
ful analysis complementary to urinary organic acid
and acylcarnitine profiles. Early diagnosis of meta-
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bolic disorders, in fact, is the first goal for the clini-
cian, as proper therapeutical intervention often pre-
vents acute life-threatening events and later
disability.
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